Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription Articles published in Aliment Pharmacol Ther Retrieve available abstracts of 576 articles: HTML format

Single Articles

June 2024
1. SONG S, Lv J, Li L, Pang Y, et al
   Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia? Authors' reply.
   Aliment Pharmacol Ther. 2024;59:1453-1454.
   PubMed    
   
   
   May 2024
2. NEDUMANNIL L, Mohamedrashed M, Bohra A, Sood S, et al
   Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease.
   Aliment Pharmacol Ther. 2024;59:1162-1163.
   PubMed    
   
   
   
3. BARTH I, Stevens CL, Strokap CJ, Campmans-Kuijpers MJE, et al
   Letter: Diet-microbiome interactions in inflammatory bowel disease-Navigating towards individualised dietary strategies.
   Aliment Pharmacol Ther. 2024;59:1154-1155.
   PubMed    
   
   
   
4. THWAITES PA, Gibson PR
   Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease. Authors' reply.
   Aliment Pharmacol Ther. 2024;59:1164-1165.
   PubMed    
   
   
   
5. SEIDELIN JB
   Editorial: Time to address quality of life in our IBD treatment-IBD nurse intervention as a key part of multimodal IBD management.
   Aliment Pharmacol Ther. 2024;59:1152-1153.
   PubMed    
   
   
   
6. GARCIA MJ, Gisbert JP, Chaparro M
   Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision? Authors' reply.
   Aliment Pharmacol Ther. 2024;59:1298-1299.
   PubMed    
   
   
   
7. DERIKX LAAP, Hoentjen F
   Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision?
   Aliment Pharmacol Ther. 2024;59:1296-1297.
   PubMed    
   
   
   
8. SHAH A, Holtmann G
   Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis-associated inflammatory bowel disease?
   Aliment Pharmacol Ther. 2024;59:1290-1291.
   PubMed    
   
   
   
9. NORGARD BM, Thorarinsson CT, Zegers FD, Kjeldsen J, et al
   The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study.
   Aliment Pharmacol Ther. 2024 May 1. doi: 10.1111/apt.18014.
   PubMed     Abstract available
   
   
   April 2024
10. SONG S, Wu Z, Lv J, Yu C, et al
    Dietary factors and patterns in relation to risk of later-onset ulcerative colitis in Chinese: A prospective study of 0.5 million people.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17963.
    PubMed     Abstract available
    
    
    
11. FUKUDA T, Yamazaki H, Miyatani Y, Sawada T, et al
    Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18013.
    PubMed     Abstract available
    
    
    
12. YIU TH, Ko Y, Pudipeddi A, Natale P, et al
    Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18006.
    PubMed     Abstract available
    
    
    
13. FERNANDEZ-CLOTET A, Ordas I, Masamunt MC, Caballol B, et al
    Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17968.
    PubMed     Abstract available
    
    
    
14. VUIJK SA, Jongsma MME, Hoeven BM, Cozijnsen MA, et al
    Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.18000.
    PubMed     Abstract available
    
    
    
15. URQUHART SA, Fletcher JG, Bruining DH
    Editorial: Foretelling the future-Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17991.
    PubMed    
    
    
    
16. OKABAYASHI S, Kobayashi T
    Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia?
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17983.
    PubMed    
    
    
    
17. ARATARI A, Scribano ML, Pugliese D, Baccolini V, et al
    Crohn's disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate-A retrospective multicentre real-world study.
    Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.18001.
    PubMed     Abstract available
    
    
    
18. KIM K, Park JJ, Yoon H, Lee J, et al
    Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.
    Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.17989.
    PubMed     Abstract available
    
    
    
19. ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
    Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
    Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
    PubMed     Abstract available
    
    
    
20. VASUDEVAN A, Con D, van Langenberg DR
    Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:1011.
    PubMed    
    
    
    
21. ASONUMA K, Sagami S, Kobayashi T
    Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights.
    Aliment Pharmacol Ther. 2024;59:1005-1006.
    PubMed    
    
    
    
22. CHETWOOD JD, Paramsothy S, Leong RW
    Letter: Thioguanine, an underutilised option in inflammatory bowel disease?
    Aliment Pharmacol Ther. 2024;59:1009-1010.
    PubMed    
    
    
    March 2024
23. AKIYAMA S, Yokoyama K, Yagi S, Shinzaki S, et al
    Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
    Aliment Pharmacol Ther. 2024 Mar 17. doi: 10.1111/apt.17961.
    PubMed     Abstract available
    
    
    
24. RICCIUTO A, Liu K, El-Matary W, Amin M, et al
    Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
    Aliment Pharmacol Ther. 2024 Mar 10. doi: 10.1111/apt.17936.
    PubMed     Abstract available
    
    
    
25. GARCIA MJ, Riestra S, Amiot A, Julsgaard M, et al
    Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
    Aliment Pharmacol Ther. 2024 Mar 6. doi: 10.1111/apt.17938.
    PubMed     Abstract available
    
    
    
26. LU C, Rosentreter R, Delisle M, White M, et al
    Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound.
    Aliment Pharmacol Ther. 2024 Mar 4. doi: 10.1111/apt.17918.
    PubMed     Abstract available
    
    
    
27. GONCZI L, Lakatos L, Ilias A, Lakatos PL, et al
    Editorial: The prevalence and outcomes of perianal Crohn's disease across the treatment eras-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:715-716.
    PubMed    
    
    
    
28. LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
    Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply.
    Aliment Pharmacol Ther. 2024;59:723-724.
    PubMed    
    
    
    
29. LAHARIE D
    Letter: Should ulcerative colitis be monitored more or less invasively?
    Aliment Pharmacol Ther. 2024;59:721-722.
    PubMed    
    
    
    
30. TASSONE D, Hartley I, Ding NS
    Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.
    Aliment Pharmacol Ther. 2024;59:713-714.
    PubMed    
    
    
    
31. VAN LIERE ELSA, de Boer NKH
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024;59:792-793.
    PubMed    
    
    
    
32. VASUDEVAN A, Con D, van Langenberg DR
    Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2024;59:794.
    PubMed    
    
    
    
33. BOKEMEYER B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, et al
    Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD(BIO-ASSIST) study).
    Aliment Pharmacol Ther. 2024 Mar 1. doi: 10.1111/apt.17926.
    PubMed     Abstract available
    
    
    February 2024
34. ERIKSSON C, Sun J, Bryder M, Broms G, et al
    Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.
    Aliment Pharmacol Ther. 2024 Feb 29. doi: 10.1111/apt.17932.
    PubMed     Abstract available
    
    
    
35. ZAMANI M, Alizadeh-Tabari S, Murad MH, Ananthakrishnan AN, et al
    Meta-analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2024 Feb 19. doi: 10.1111/apt.17919.
    PubMed     Abstract available
    
    
    
36. SAGAMI S, Kobayashi T
    Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety.
    Aliment Pharmacol Ther. 2024;59:579-580.
    PubMed    
    
    
    
37. PANACCIONE R
    Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply.
    Aliment Pharmacol Ther. 2024;59:581-582.
    PubMed    
    
    
    
38. VASUDEVAN A, Con D, De Cruz P, Sparrow MP, et al
    Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
    Aliment Pharmacol Ther. 2024;59:504-514.
    PubMed     Abstract available
    
    
    January 2024
39. CON D, Srinivasan A
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.
    Aliment Pharmacol Ther. 2024;59:140-141.
    PubMed    
    
    
    
40. VAN DE MEEBERG MM, Fidder HH, de Jonge R, Bouma G, et al
    Editorial: Monitoring methotrexate polyglutamates in Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:120-121.
    PubMed    
    
    
    
41. BARCLAY ML, Stamp LK
    Editorial: Monitoring methotrexate polyglutamates in Crohn's disease.
    Aliment Pharmacol Ther. 2024;59:118-119.
    PubMed    
    
    
    
42. PRAY C, Narula N
    Editorial: Moving towards prognostic endoscopic scoring in IBD.
    Aliment Pharmacol Ther. 2024;59:132-133.
    PubMed    
    
    
    December 2023
43. GONCZI L, Lakatos L, Golovics PA, Angyal D, et al
    Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades - Results from a population-based study over four decades.
    Aliment Pharmacol Ther. 2023 Dec 19. doi: 10.1111/apt.17836.
    PubMed     Abstract available
    
    
    
44. MEYER A, Dong C, Chan SSM, Touvier M, et al
    Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Dec 15. doi: 10.1111/apt.17835.
    PubMed     Abstract available
    
    
    
45. DESAI A, Regueiro M, Kochhar GS
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    
    
    
    
46. SOHN J
    Editorial: Unravelling the relationship between periodontal disease and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    
    
    
    
47. REZAZADEH ARDABILI A, Janssen L, Mujagic Z
    Letter: Abdominal pain in patients with inflammatory bowel disease in remission - A look beyond psychosocial factors. Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    
    
    
    
48. CHANG HC, Gau SY
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    
    
    
    
49. BASSOTTI G, Villanacci V, Maconi G
    Letter: Abdominal pain in inflammatory bowel disease patients in remission-A look beyond psychosocial factors.
    Aliment Pharmacol Ther. 2023;58.
    PubMed    
    
    
    November 2023
50. BUISSON A, Nachury M, Bazoge M, Yzet C, et al
    Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
    Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17822.
    PubMed     Abstract available
    
    
    
51. PEYRIN-BIROULET L, Vermeire S, D'Haens G, Panes J, et al
    Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
    Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17751.
    PubMed     Abstract available
    
    
    
52. PANACCIONE R, Danese S, Zhou W, Klaff J, et al
    Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Nov 27. doi: 10.1111/apt.17816.
    PubMed     Abstract available
    
    
    
53. BOKEMEYER B, Plachta-Danielzik S
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply.
    Aliment Pharmacol Ther. 2023 Nov 4. doi: 10.1111/apt.17796.
    PubMed    
    
    
    
54. KELLER JJ, Terveer EM
    Editorial: Continuous monitoring to improve outcome of treatment-the next step towards safe and effective faecal microbiota transplantation.
    Aliment Pharmacol Ther. 2023;58:946-947.
    PubMed    
    
    
    
55. DAN L, Wang X, Chen J
    Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD. Authors' reply.
    Aliment Pharmacol Ther. 2023;58:940-941.
    PubMed    
    
    
    
56. LOPES EW, Khalili H
    Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD.
    Aliment Pharmacol Ther. 2023;58:938-939.
    PubMed    
    
    
    October 2023
57. SPARTZ EJ, DeDecker LC, Fansiwala KM, Noorian S, et al
    Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Oct 24. doi: 10.1111/apt.17777.
    PubMed     Abstract available
    
    
    
58. LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
    The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Oct 16. doi: 10.1111/apt.17753.
    PubMed     Abstract available
    
    
    
59. DAJTI E, Frazzoni L, Iascone V, Secco M, et al
    Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
    PubMed     Abstract available
    
    
    
60. KAYAL M, Meringer H, Martin L, Colombel JF, et al
    Scores used to predict outcomes in acute severe ulcerative colitis: A systematic review.
    Aliment Pharmacol Ther. 2023 Oct 11. doi: 10.1111/apt.17731.
    PubMed     Abstract available
    
    
    
61. RIGGOTT C, Fairbrass KM, Black CJ, Gracie DJ, et al
    Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study.
    Aliment Pharmacol Ther. 2023 Oct 4. doi: 10.1111/apt.17735.
    PubMed     Abstract available
    
    
    
62. WILLIAMS KM, Challa PK, Lopes EW, Burke KE, et al
    Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US.
    Aliment Pharmacol Ther. 2023 Oct 2. doi: 10.1111/apt.17732.
    PubMed     Abstract available
    
    
    
63. TASSONE D, Hartley I, Ding NS
    Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58:729-730.
    PubMed    
    
    
    
64. ANDREW B, Zhou A, Trinh S, Srinivasan A, et al
    Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed.
    Aliment Pharmacol Ther. 2023;58:838-839.
    PubMed    
    
    
    
65. OH SJ, Kim HJ, Lee CK
    Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:840-841.
    PubMed    
    
    
    
66. ARULJOTHY A, Singh S, Narula N, Moran GW, et al
    Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
    Aliment Pharmacol Ther. 2023;58:740-762.
    PubMed     Abstract available
    
    
    
67. REZAZADEH ARDABILI A, Van Bodegraven AA
    Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses.
    Aliment Pharmacol Ther. 2023;58:832-833.
    PubMed    
    
    
    September 2023
68. VAN DE MEEBERG MM, Fidder HH, Oldenburg B, Sundaresan J, et al
    Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17719.
    PubMed     Abstract available
    
    
    
69. FAQERAH N, Walker D, Gerasimidis K
    Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17720.
    PubMed     Abstract available
    
    
    
70. JANSSEN LM, Rezazadeh Ardabili A, Romberg-Camps MJL, Winkens B, et al
    Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors.
    Aliment Pharmacol Ther. 2023 Sep 19. doi: 10.1111/apt.17718.
    PubMed     Abstract available
    
    
    
71. SCHREIBER S, Rogler G, Watanabe M, Vermeire S, et al
    Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
    Aliment Pharmacol Ther. 2023 Sep 18. doi: 10.1111/apt.17674.
    PubMed     Abstract available
    
    
    
72. ANDREW B, Srinivasan A, Zhou A, Vasudevan A, et al
    Letter: Elderly onset inflammatory bowel disease-Treat to target approach is still warranted.
    Aliment Pharmacol Ther. 2023;58:556-557.
    PubMed    
    
    
    
73. YAMAMOTO T
    Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:546-547.
    PubMed    
    
    
    
74. DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
    Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.
    Aliment Pharmacol Ther. 2023;58:492-502.
    PubMed     Abstract available
    
    
    
75. WU X, Yang Y
    Letter: Chinese herbal medicine Curcumin-QingDai (CurQD) - A good treatment option for active ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:640.
    PubMed    
    
    
    
76. DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
    Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:634-635.
    PubMed    
    
    
    
77. KEDIA S, Ahuja V
    Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails.
    Aliment Pharmacol Ther. 2023;58:632-633.
    PubMed    
    
    
    
78. YANAI H, Salomon N, Ben-Horin S, Kopylov U, et al
    Letter: Chinese herbal medicine Curcumin-QingDai (CurQD)-A good treatment option for active ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:641.
    PubMed    
    
    
    August 2023
79. HONAP S, Peyrin-Biroulet L
    Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?
    Aliment Pharmacol Ther. 2023 Aug 21. doi: 10.1111/apt.17684.
    PubMed     Abstract available
    
    
    
80. EVERHOV AH, Soderling J, Befrits G, Khalili H, et al
    Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden.
    Aliment Pharmacol Ther. 2023 Aug 18. doi: 10.1111/apt.17675.
    PubMed     Abstract available
    
    
    
81. WOELFEL S, Dutschler J, Konig M, Dulovic A, et al
    STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Aug 12. doi: 10.1111/apt.17661.
    PubMed     Abstract available
    
    
    
82. LOBATON T, Truyens M
    Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
    Aliment Pharmacol Ther. 2023;58:359-360.
    PubMed    
    
    
    
83. KANE S
    Editorial: Increased risk of cervical dysplasia with immunomodulator use in IBD.
    Aliment Pharmacol Ther. 2023;58:357-358.
    PubMed    
    
    
    
84. KIRCHGESNER J, Beaugerie L
    Editorial: Pip pip to PIPs (post- inflammatory polyps) as a neoplasia risk factor in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:363.
    PubMed    
    
    
    
85. TASSONE D, Hartley I, Ding NS
    Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58:376-377.
    PubMed    
    
    
    
86. VELAYOS FS
    Editorial: Pip pip to PIP's (post-inflammatory polyps) as a neoplasia risk factor in IBD?
    Aliment Pharmacol Ther. 2023;58:361-362.
    PubMed    
    
    
    July 2023
87. DENG M, Dan L, Ye S, Chen X, et al
    Higher dietary fibre intake is associated with lower risk of inflammatory bowel disease: prospective cohort study.
    Aliment Pharmacol Ther. 2023 Jul 18. doi: 10.1111/apt.17649.
    PubMed     Abstract available
    
    
    
88. MIN Y, Wei X, Peng X
    Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer?
    Aliment Pharmacol Ther. 2023;58:143-144.
    PubMed    
    
    
    
89. MASSIRONI S, Vigano C, Danese S
    Letter: Mendelian randomization - new perspective in inflammatory bowel disease and pancreatic cancer? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:145-146.
    PubMed    
    
    
    
90. MILES M, Nasser Y
    Editorial: faecal incontinence in ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58:114-115.
    PubMed    
    
    
    
91. CHAN P, Connor S, Huang V, Karimi N, et al
    Letter: expanding the role for decision aids in IBD into pregnancy-related topics.
    Aliment Pharmacol Ther. 2023;58:141-142.
    PubMed    
    
    
    
92. ESTEVINHO MM, Magro F
    Editorial: elderly onset inflammatory bowel disease - clues from the largest population-based cohort study.
    Aliment Pharmacol Ther. 2023;58:116-117.
    PubMed    
    
    
    
93. HUDSON AS, Huynh HQ
    Editorial: Predicting paediatric ulcerative colitis outcomes-how can we improve?
    Aliment Pharmacol Ther. 2023;58:258-259.
    PubMed    
    
    
    
94. OH SJ, Kim HJ, Lee CK
    Editorial: Antibiotics and risk of IBD-Can we close the books? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:256-257.
    PubMed    
    
    
    
95. EBRAHIMI F, Forss A
    Editorial: Antibiotics and risk of IBD-Can we close the books?
    Aliment Pharmacol Ther. 2023;58:254-255.
    PubMed    
    
    
    
96. BACSUR P, Ilias A, Resal T, Kata D, et al
    Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.
    Aliment Pharmacol Ther. 2023;58:262-263.
    PubMed    
    
    
    June 2023
97. D'HAENS G, Peyrin-Biroulet L, Marks DJB, Lisi E, et al
    A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
    Aliment Pharmacol Ther. 2023 Jun 16. doi: 10.1111/apt.17557.
    PubMed     Abstract available
    
    
    
98. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Efken P, et al
    Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO(IBD) -study.
    Aliment Pharmacol Ther. 2023 Jun 15. doi: 10.1111/apt.17616.
    PubMed     Abstract available
    
    
    
99. NGUYEN AL, Burns M, Herath M, Lambell K, et al
    Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023 Jun 12. doi: 10.1111/apt.17607.
    PubMed     Abstract available
    
    
    
100. KOCHHAR GS, Desai A, Farraye FA, Cross RK, et al
     Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
     Aliment Pharmacol Ther. 2023 Jun 9. doi: 10.1111/apt.17570.
     PubMed     Abstract available
     
     
     
101. MACALUSO FS, Orlando A
     Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?
     Aliment Pharmacol Ther. 2023;57:1343-1344.
     PubMed    
     
     
     
102. CALDERA F, Spaulding AC, Hayney MS, Farraye FA, et al
     Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation? Authors' reply.
     Aliment Pharmacol Ther. 2023;57:1345-1346.
     PubMed    
     
     
     
103. CHEN P, Chen F
     Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients.
     Aliment Pharmacol Ther. 2023;57:1349-1350.
     PubMed    
     
     
     
104. IKEGAMI S, Nakamura M, Honda T, Kawashima H, et al
     Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply.
     Aliment Pharmacol Ther. 2023;57:1351-1352.
     PubMed    
     
     
     
105. HANZEL J, Drobne D
     Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
     Aliment Pharmacol Ther. 2023;57:1469-1470.
     PubMed    
     
     
     
106. SETHI S, Kumar A, Dias S, Blackwell J, et al
     Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply.
     Aliment Pharmacol Ther. 2023;57:1455-1456.
     PubMed    
     
     
     
107. FUMERY M, Roblin X
     Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply.
     Aliment Pharmacol Ther. 2023;57:1471-1472.
     PubMed    
     
     
     
108. ROBLIN X, Nancey S
     Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?
     Aliment Pharmacol Ther. 2023;57:1453-1454.
     PubMed    
     
     
     
109. POLLOK RC, Jayasooriya N, Baillie S, Blackwell J, et al
     Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach. Authors' reply.
     Aliment Pharmacol Ther. 2023;57:1479.
     PubMed    
     
     
     
110. CHANG HC, Gau SY
     Letter: histologic disease activity and colorectal neoplasia risk.
     Aliment Pharmacol Ther. 2023;57:1480.
     PubMed    
     
     
     
111. LUCAS S, Chauhan A, Garg M
     Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach.
     Aliment Pharmacol Ther. 2023;57:1477-1478.
     PubMed    
     
     
     May 2023
112. ATIA O, Klomberg RCW, de Ridder L, Kemos P, et al
     Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort.
     Aliment Pharmacol Ther. 2023 May 29. doi: 10.1111/apt.17544.
     PubMed     Abstract available
     
     
     
113. KREIJNE JE, Goetgebuer RL, Erler NS, De Boer NK, et al
     Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023 May 23. doi: 10.1111/apt.17555.
     PubMed     Abstract available
     
     
     
114. YANAI H, Salomon N, Lahat A, Ungar B, et al
     Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.
     Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17538.
     PubMed     Abstract available
     
     
     
115. OH SJ, Kim HJ, Lee CK
     A dose-dependent increase in the risk of inflammatory bowel disease after exposure to broad-spectrum antibiotics: A national population study in Korea.
     Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17542.
     PubMed     Abstract available
     
     
     
116. CHEN J, Ruan X, Yuan S, Theodoratou E, et al
     Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation-authors' reply.
     Aliment Pharmacol Ther. 2023;57:1034-1035.
     PubMed    
     
     
     
117. VAN RULER O, Arkenbosch JHC, van der Woude CJ
     Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease. Authors' reply.
     Aliment Pharmacol Ther. 2023;57:1030-1031.
     PubMed    
     
     
     
118. BURISCH J
     Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?
     Aliment Pharmacol Ther. 2023;57:1044-1045.
     PubMed    
     
     
     
119. DART RJ
     Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease.
     Aliment Pharmacol Ther. 2023;57:1028-1029.
     PubMed    
     
     
     
120. MEYER A, Amiot A, Carbonnel F
     Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.
     Aliment Pharmacol Ther. 2023;57:1032-1033.
     PubMed    
     
     
     
121. CHEN J, Ruan X, Yuan S, Theodoratou E, et al
     Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.
     Aliment Pharmacol Ther. 2023;57:1048-1049.
     PubMed    
     
     
     
122. GEERTSEMA S, van Goor H, Dijkstra G, Faber KN, et al
     Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases - moving towards causal associations.
     Aliment Pharmacol Ther. 2023;57:1046-1047.
     PubMed    
     
     
     
123. SONNENBERG A, Genta RM
     Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter? Authors' reply.
     Aliment Pharmacol Ther. 2023;57:1155-1156.
     PubMed    
     
     
     
124. SZIGETI R, Krishna M, Kellermayer R
     Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype?
     Aliment Pharmacol Ther. 2023;57:1192-1193.
     PubMed    
     
     
     
125. POLLOK RC, Baillie S, Jayasooriya N, Blackwell J, et al
     Letter: diagnostic delay in inflammatory bowel disease-Authors' reply.
     Aliment Pharmacol Ther. 2023;57:1205-1206.
     PubMed    
     
     
     
126. ATIA O, Goren I, Yanai H
     Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease-authors' reply.
     Aliment Pharmacol Ther. 2023;57:1184-1185.
     PubMed    
     
     
     
127. ANDERSON RP
     Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter?
     Aliment Pharmacol Ther. 2023;57:1153-1154.
     PubMed    
     
     
     
128. TASSONE D, Gilmore R, Lee T, Ding NS, et al
     Letter: diagnostic delay in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023;57:1203-1204.
     PubMed    
     
     
     
129. JAYASOORIYA N, Saxena S, Pollok RC
     Letter: fulminant onset complicated inflammatory bowel disease (IBD) - a unique subtype? Authors' reply.
     Aliment Pharmacol Ther. 2023;57:1194-1195.
     PubMed    
     
     
     
130. CHANG HC, Gau SY
     Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease.
     Aliment Pharmacol Ther. 2023;57:1183.
     PubMed    
     
     
     April 2023
131. CASANOVA MJ, Nantes O, Varela P, Vela-Gonzalez M, et al
     Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
     Aliment Pharmacol Ther. 2023 Apr 23. doi: 10.1111/apt.17525.
     PubMed     Abstract available
     
     
     
132. NORGARD BM, Zegers FD, Knudsen T, Kjeldsen J, et al
     Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
     Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17520.
     PubMed     Abstract available
     
     
     
133. BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Helwig U, et al
     Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
     Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17512.
     PubMed     Abstract available
     
     
     
134. GOLD SL, Raman M, Sands BE, Ungaro R, et al
     Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17498.
     PubMed     Abstract available
     
     
     
135. OLIVERA PA, Lasa JS, Peretto G, Zuily S, et al
     Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
     Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17509.
     PubMed     Abstract available
     
     
     
136. VASANT DH, Nigam GB, Bate S, Hamdy S, et al
     The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross-sectional study.
     Aliment Pharmacol Ther. 2023 Apr 3. doi: 10.1111/apt.17502.
     PubMed     Abstract available
     
     
     
137. GUPTA A, Kedia S, Ahuja V
     Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs-double whammy?
     Aliment Pharmacol Ther. 2023;57:815-816.
     PubMed    
     
     
     
138. SPEEDY AP, Wall CL
     Editorial: Interdisciplinary and multidisciplinary approach to malnutrition in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023;57:907-908.
     PubMed    
     
     
     March 2023
139. WOLF T, Lewis A, Beaugerie L, Svrcek M, et al
     Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps.
     Aliment Pharmacol Ther. 2023 Mar 31. doi: 10.1111/apt.17495.
     PubMed     Abstract available
     
     
     
140. CALDERA F, Spaulding AC, Borah B, Moriarty J, et al
     Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023 Mar 10. doi: 10.1111/apt.17454.
     PubMed     Abstract available
     
     
     
141. ATIA O, Goren I, Fischler TS, Weisband YL, et al
     5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
     Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17419.
     PubMed     Abstract available
     
     
     
142. MELTON SL, Taylor KM, Gibson PR, Halmos EP, et al
     Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease.
     Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17451.
     PubMed     Abstract available
     
     
     
143. CHANG HC, Gau SY
     Letter: sleep duration and the incidence of inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023;57:595-596.
     PubMed    
     
     
     
144. COLMAN RJ, Minar P
     Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2023;57:567-568.
     PubMed    
     
     
     
145. HORSFALL E, Irwin J
     Editorial: inflammatory bowel disease and sleep.
     Aliment Pharmacol Ther. 2023;57:573-574.
     PubMed    
     
     
     
146. CORTESI PA, Fiorino G, Mantovani LG, Danese S, et al
     Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay? Authors' reply.
     Aliment Pharmacol Ther. 2023;57:571-572.
     PubMed    
     
     
     
147. BARBER GE, Gubatan J
     Editorial: treat-to-target in ulcerative colitis clinical management-a small price to pay?
     Aliment Pharmacol Ther. 2023;57:569-570.
     PubMed    
     
     
     
148. YUAN S, Chen J, Li X
     Editorial: IBD and sleep-authors' reply.
     Aliment Pharmacol Ther. 2023;57:575-576.
     PubMed    
     
     
     
149. VUIJK SA, de Ridder L
     Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023;57:565-566.
     PubMed    
     
     
     
150. PEYRIN-BIROULET L, Ghosh S, Lee SD, Lee WJ, et al
     Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
     Aliment Pharmacol Ther. 2023;57:496-508.
     PubMed     Abstract available
     
     
     
151. BUISSON A
     Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Authors' reply.
     Aliment Pharmacol Ther. 2023;57:735-736.
     PubMed    
     
     
     
152. VOLKERS A, Straatmijer T, Duijvestein M, Lowenberg M, et al
     Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.
     Aliment Pharmacol Ther. 2023;57:743-744.
     PubMed    
     
     
     
153. ERNEST-SUAREZ K, Lu C
     Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?
     Aliment Pharmacol Ther. 2023;57:733-734.
     PubMed    
     
     
     
154. RICHARD N, Vuitton L, Fumery M
     Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023;57:741-742.
     PubMed    
     
     
     February 2023
155. FUMERY M, Nancey S, Filippi J, Altwegg R, et al
     Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
     Aliment Pharmacol Ther. 2023 Feb 27. doi: 10.1111/apt.17421.
     PubMed     Abstract available
     
     
     
156. REGEV S, Schwartz D, Sarid O, Goren G, et al
     Randomised clinical trial: Psychological intervention improves work productivity and daily activity by reducing abdominal pain and fatigue in Crohn's disease.
     Aliment Pharmacol Ther. 2023 Feb 2. doi: 10.1111/apt.17399.
     PubMed     Abstract available
     
     
     
157. SONNENBERG A, Genta RM
     Case-control study of the concurrence of coeliac disease with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023 Feb 2. doi: 10.1111/apt.17408.
     PubMed     Abstract available
     
     
     
158. CHOWDHURY R, Kane SV
     Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study.
     Aliment Pharmacol Ther. 2023;57:349-350.
     PubMed    
     
     
     
159. VESTERGAARD T, Kelsen J, Julsgaard M
     Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease - a Danish cohort study. Authors' reply.
     Aliment Pharmacol Ther. 2023;57:351-352.
     PubMed    
     
     
     January 2023
160. CHEN J, Ruan X, Yuan S, Deng M, et al
     Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.
     Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17392.
     PubMed     Abstract available
     
     
     
161. TAXONERA C, Olivares D, Lopez-Garcia ON, Alba C, et al
     Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
     Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17386.
     PubMed     Abstract available
     
     
     
162. KHAN N, Mahmud N, Patel M, Sundararajan R, et al
     Risk of severe and opportunistic infections and the impact of SARS-COV-2 on this risk in a nationwide cohort of patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17393.
     PubMed     Abstract available
     
     
     
163. IKEGAMI S, Nakamura M, Honda T, Yamamura T, et al
     Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double-blind, placebo-controlled pilot study.
     Aliment Pharmacol Ther. 2023 Jan 16. doi: 10.1111/apt.17387.
     PubMed     Abstract available
     
     
     
164. DUA A, Corson M, Sauk JS, Jaffe N, et al
     Impact of malnutrition and nutrition support in hospitalised patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023 Jan 13. doi: 10.1111/apt.17389.
     PubMed     Abstract available
     
     
     
165. JAYASOORIYA N, Baillie S, Blackwell J, Bottle A, et al
     Systematic review with meta-analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2023 Jan 10. doi: 10.1111/apt.17370.
     PubMed     Abstract available
     
     
     
166. LAHARIE D, Riviere P
     Editorial: selecting therapy for ulcerative colitis-think a step ahead.
     Aliment Pharmacol Ther. 2023;57:161-162.
     PubMed    
     
     
     
167. WOELFEL S, Dutschler J, Konig M, Graf N, et al
     Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
     Aliment Pharmacol Ther. 2023;57:103-116.
     PubMed     Abstract available
     
     
     
168. REIJNTJES MA, de Voogd FAE, Buskens CJ, Gecse KB, et al
     Editorial: routine use of intestinal ultrasound in ulcerative colitis-are we missing the appendix? Authors' reply.
     Aliment Pharmacol Ther. 2023;57:255-256.
     PubMed    
     
     
     
169. SCRIBANO ML
     Editorial: shared decision-making intervention in patients with Crohn's disease-a personalised, patient-centred approach.
     Aliment Pharmacol Ther. 2023;57:263-264.
     PubMed    
     
     
     
170. ERNEST-SUAREZ K, Novak K
     Editorial: routine use of intestinal ultrasound in ulcerative colitis-are we missing the appendix?
     Aliment Pharmacol Ther. 2023;57:253-254.
     PubMed    
     
     
     
171. LIWINSKI T, Hubener S, Henze L, Hubener P, et al
     A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.
     Aliment Pharmacol Ther. 2023;57:224-236.
     PubMed     Abstract available
     
     
     December 2022
172. DIN S, Selinger CP, Black CJ, Ford AC, et al
     Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Dec 31. doi: 10.1111/apt.17379.
     PubMed     Abstract available
     
     
     
173. ARKENBOSCH JHC, van Ruler O, Dwarkasing RS, Fuhler GM, et al
     Stromal vascular fraction with platelet-rich plasma injection during surgery is feasible and safe in treatment-refractory perianal fistulising Crohn's disease: A pilot study.
     Aliment Pharmacol Ther. 2022 Dec 26. doi: 10.1111/apt.17347.
     PubMed     Abstract available
     
     
     
174. FUMERY M, Defrance A, Roblin X, Altwegg R, et al
     Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
     Aliment Pharmacol Ther. 2022 Dec 19. doi: 10.1111/apt.17358.
     PubMed     Abstract available
     
     
     
175. VESTERGAARD T, Julsgaard M, Rosok JF, Vestergaard SV, et al
     Predictors of disease activity during pregnancy in women with inflammatory bowel disease-a Danish cohort study.
     Aliment Pharmacol Ther. 2022 Dec 14. doi: 10.1111/apt.17348.
     PubMed     Abstract available
     
     
     
176. SETHI S, Dias S, Kumar A, Blackwell J, et al
     Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Dec 9. doi: 10.1111/apt.17313.
     PubMed     Abstract available
     
     
     
177. VUIJK SA, de Ridder L
     Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;56.
     PubMed    
     
     
     
178. KULYK A, Shafer LA, Graff LA, Stone J, et al
     Urgency for bowel movements is a highly discriminatory symptom of active disease in persons with IBD (the Manitoba Living with IBD study).
     Aliment Pharmacol Ther. 2022;56.
     PubMed     Abstract available
     
     
     November 2022
179. BUISSON A, Nachury M, Guilmoteau T, Altwegg R, et al
     Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
     Aliment Pharmacol Ther. 2022 Nov 19. doi: 10.1111/apt.17305.
     PubMed     Abstract available
     
     
     
180. CORTESI PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, et al
     Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
     Aliment Pharmacol Ther. 2022 Nov 15. doi: 10.1111/apt.17261.
     PubMed     Abstract available
     
     
     
181. ZISMAN-ILANI Y, Thompson KD, Siegel LS, Mackenzie T, et al
     Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.
     Aliment Pharmacol Ther. 2022 Nov 14. doi: 10.1111/apt.17286.
     PubMed     Abstract available
     
     
     
182. YUAN S, Sun Y, Tan X, Geng J, et al
     Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study.
     Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17285.
     PubMed     Abstract available
     
     
     
183. EVERHOV AH, Olen O
     Editorial: colorectal cancer in elderly-onset IBD-what is the risk? Authors' reply.
     Aliment Pharmacol Ther. 2022;56:1423-1424.
     PubMed    
     
     
     
184. WEISS A, Buchner AM
     Editorial: colorectal cancer in elderly-onset inflammatory bowel disease-what is the risk?
     Aliment Pharmacol Ther. 2022;56:1421-1422.
     PubMed    
     
     
     
185. LEE KE, Faye AS
     Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. Authors' reply.
     Aliment Pharmacol Ther. 2022;56:1427-1428.
     PubMed    
     
     
     
186. SAHYOUN L, Dahiya DS, Cheng CI, Sultan K, et al
     Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism.
     Aliment Pharmacol Ther. 2022;56:1425-1426.
     PubMed    
     
     
     
187. BEZZIO C, Alimenti E, Saibeni S
     Letter: immune-mediated inflammatory diseases and inflammatory bowel disease-are we ready for a Copernican revolution?
     Aliment Pharmacol Ther. 2022;56:1429-1430.
     PubMed    
     
     
     
188. DAHL EK, Abed OK, Kjeldsen J, Donia M, et al
     Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis.
     Aliment Pharmacol Ther. 2022;56:1370-1382.
     PubMed     Abstract available
     
     
     
189. NORGARD BM, Friedman S, Kjeldsen J, Nielsen J, et al
     The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.
     Aliment Pharmacol Ther. 2022;56:1349-1360.
     PubMed     Abstract available
     
     
     
190. RONNOW SAND J, Troelsen FS, Horvath-Puho E, Henderson VW, et al
     Letter: comedication use and dementia risk in patients with inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2022;56:1505-1506.
     PubMed    
     
     
     
191. CHANG HC, Gau SY
     Letter: comedication use and dementia risk in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;56:1503-1504.
     PubMed    
     
     
     
192. REIJNTJES MA, de Voogd FAE, Bemelman WA, Hompes R, et al
     Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls - a prospective cohort study.
     Aliment Pharmacol Ther. 2022 Nov 1. doi: 10.1111/apt.17267.
     PubMed     Abstract available
     
     
     October 2022
193. COLMAN RJ, Mizuno T, Fukushima K, Haslam DB, et al
     Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
     Aliment Pharmacol Ther. 2022 Oct 31. doi: 10.1111/apt.17277.
     PubMed     Abstract available
     
     
     
194. STRAATMIJER T, van Schaik FDM, Bodelier AGL, Visschedijk M, et al
     Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
     Aliment Pharmacol Ther. 2022 Oct 25. doi: 10.1111/apt.17248.
     PubMed     Abstract available
     
     
     
195. SAIFUDDIN A, Kent AJ, Mehta SJ, Hicks LC, et al
     Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
     Aliment Pharmacol Ther. 2022 Oct 5. doi: 10.1111/apt.17223.
     PubMed     Abstract available
     
     
     
196. BURGESS CJ, Jackson R, Chalmers I, Russell RK, et al
     The inexorable increase of biological exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study.
     Aliment Pharmacol Ther. 2022 Oct 4. doi: 10.1111/apt.17217.
     PubMed     Abstract available
     
     
     
197. BURISCH J
     Editorial: trends in the epidemiology of inflammatory bowel disease in Korea.
     Aliment Pharmacol Ther. 2022;56:1207-1208.
     PubMed    
     
     
     
198. BODGER K
     Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA.
     Aliment Pharmacol Ther. 2022;56:1211-1212.
     PubMed    
     
     
     
199. SHIM JO
     Editorial: trends in the epidemiology of inflammatory bowel disease in Korea - author's reply.
     Aliment Pharmacol Ther. 2022;56:1209-1210.
     PubMed    
     
     
     
200. LEE KE, Faye AS
     Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA-authors' reply.
     Aliment Pharmacol Ther. 2022;56:1213-1214.
     PubMed    
     
     
     
201. CHOI SY, Kim ES, Jeon TY, Lee YM, et al
     Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics.
     Aliment Pharmacol Ther. 2022;56:1146-1156.
     PubMed     Abstract available
     
     
     
202. SHIN A
     Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;56:1300-1301.
     PubMed    
     
     
     
203. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
     Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2022;56:1302-1303.
     PubMed    
     
     
     September 2022
204. AVNI-BIRON I, Mishael T, Zittan E, Livne-Margolin M, et al
     Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.
     Aliment Pharmacol Ther. 2022 Sep 27. doi: 10.1111/apt.17224.
     PubMed     Abstract available
     
     
     
205. BLACK J, Sweeney L, Yuan Y, Singh H, et al
     Systematic review: the role of psychological stress in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Sep 8. doi: 10.1111/apt.17202.
     PubMed     Abstract available
     
     
     
206. ROSIOU K, Selinger CP
     Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2022;56:898-899.
     PubMed    
     
     
     
207. HAYDEK JP, Scott FI
     Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD.
     Aliment Pharmacol Ther. 2022;56:896-897.
     PubMed    
     
     
     
208. BERTANI L, Trico D
     Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue.
     Aliment Pharmacol Ther. 2022;56:903-904.
     PubMed    
     
     
     
209. HUDSON AS, Wine E
     Editorial: further support for exclusive enteral nutrition in paediatric Crohn's disease.
     Aliment Pharmacol Ther. 2022;56:900-901.
     PubMed    
     
     
     
210. KANE S
     Editorial: paternal use of IBD therapies and risk of infant infection.
     Aliment Pharmacol Ther. 2022;56:902.
     PubMed    
     
     
     
211. LIN S, Chanchlani N, Carbery I, Janjua M, et al
     Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naive patients with active luminal Crohn's disease?
     Aliment Pharmacol Ther. 2022;56:783-793.
     PubMed     Abstract available
     
     
     
212. ATIA O, Pujol-Muncunill G, Navas-Lopez VM, Orlanski-Meyer E, et al
     Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix.
     Aliment Pharmacol Ther. 2022;56:794-801.
     PubMed     Abstract available
     
     
     
213. LIMA CCG, Peerani F
     Editorial: IBD and the risk of dementia - the jury is still out.
     Aliment Pharmacol Ther. 2022;56:1078-1079.
     PubMed    
     
     
     
214. LOPES EW, Khalili H
     Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;56:1086-1087.
     PubMed    
     
     
     
215. FU T, Wang X, Chen J
     Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2022;56:1088-1089.
     PubMed    
     
     
     
216. HENDERSON P
     Editorial: earning potential in paediatric-onset IBD-a complex interplay.
     Aliment Pharmacol Ther. 2022;56:1084-1085.
     PubMed    
     
     
     
217. ZHAO M, Lirhus S, Lordal M, Langholz E, et al
     Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
     Aliment Pharmacol Ther. 2022;56:989-1006.
     PubMed     Abstract available
     
     
     
218. VOLKERS A, Straatmijer T, Duijvestein M, Sales A, et al
     Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
     Aliment Pharmacol Ther. 2022;56:1044-1054.
     PubMed     Abstract available
     
     
     August 2022
219. CHANCHLANI N, Lin S, Auth MK, Lee CL, et al
     Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
     Aliment Pharmacol Ther. 2022 Aug 29. doi: 10.1111/apt.17170.
     PubMed     Abstract available
     
     
     
220. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
     Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
     Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
     PubMed     Abstract available
     
     
     
221. IRVING PM, Leung Y, Dubinsky MC
     Review article: guide to tofacitinib dosing in patients with ulcerative colitis.
     Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17185.
     PubMed     Abstract available
     
     
     
222. MALMBORG P, Everhov AH, Soderling J, Ludvigsson JF, et al
     Earnings during adulthood in patients with childhood-onset inflammatory bowel disease: A nationwide population-based cohort study.
     Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17148.
     PubMed     Abstract available
     
     
     
223. EVERHOV AH, Erichsen R, Jaras J, Pedersen L, et al
     Colorectal cancer in elderly-onset inflammatory bowel disease: A 1969-2017 Scandinavian register-based cohort study.
     Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17175.
     PubMed     Abstract available
     
     
     
224. SOHOULI MH, Fatahi S, Farahmand F, Alimadadi H, et al
     Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease.
     Aliment Pharmacol Ther. 2022;56:384-395.
     PubMed     Abstract available
     
     
     
225. TAXONERA C
     Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis-Author's reply.
     Aliment Pharmacol Ther. 2022;56:737-738.
     PubMed    
     
     
     
226. HAWTHORNE AB, Lamb CA
     Editorial: quality assessment in IBD in high resource countries can lead to quality improvement clues for IBD management worldwide-authors' reply.
     Aliment Pharmacol Ther. 2022;56:743.
     PubMed    
     
     
     
227. MANTZARIS GJ, Papamichael K
     Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis.
     Aliment Pharmacol Ther. 2022;56:735-736.
     PubMed    
     
     
     
228. PUGLIESE D, Privitera G, Armuzzi A
     Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.
     Aliment Pharmacol Ther. 2022;56:733-734.
     PubMed    
     
     
     
229. BERNSTEIN CN
     Editorial: quality assessment in IBD in high-resource countries can lead to quality improvement clues for IBD management worldwide.
     Aliment Pharmacol Ther. 2022;56:741-742.
     PubMed    
     
     
     
230. KEEFER L, Shapiro MJ
     Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts.
     Aliment Pharmacol Ther. 2022;56:744-745.
     PubMed    
     
     
     
231. LEE H, Khan N
     Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study.
     Aliment Pharmacol Ther. 2022;56:731-732.
     PubMed    
     
     
     
232. GOLD SL, Raman M
     Editorial: a formula shake each day keeps the complications away - the tolerability and effect of orally-delivered enteral nutrition in improving post-operative outcomes in patients with Crohn's disease.
     Aliment Pharmacol Ther. 2022;56:739-740.
     PubMed    
     
     
     
233. SWAMINATHAN A, Mules TC, Gearry RB
     Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts. Authors' reply.
     Aliment Pharmacol Ther. 2022;56:746-747.
     PubMed    
     
     
     
234. MEADE S, Patel KV, Luber RP, O'Hanlon D, et al
     A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre.
     Aliment Pharmacol Ther. 2022;56:646-663.
     PubMed     Abstract available
     
     
     
235. BOURGONJE AR, Alexdottir MS, Otten AT, Loveikyte R, et al
     Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.
     Aliment Pharmacol Ther. 2022;56:675-693.
     PubMed     Abstract available
     
     
     July 2022
236. FAYE AS, Lee KE, Dodson J, Chodosh J, et al
     Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis.
     Aliment Pharmacol Ther. 2022 Jul 25. doi: 10.1111/apt.17162.
     PubMed     Abstract available
     
     
     
237. FU T, Chen H, Chen X, Sun Y, et al
     Sugar-sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants.
     Aliment Pharmacol Ther. 2022 Jul 18. doi: 10.1111/apt.17149.
     PubMed     Abstract available
     
     
     
238. REZAZADEH ARDABILI A, Jeuring S, Mujagic Z, Oostenbrug L, et al
     Classic drugs in the time of new drugs: Real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17128.
     PubMed     Abstract available
     
     
     
239. CHOE YJ, Han K, Shim JO
     Treatment patterns of anti-tumour necrosis factor-alpha and prognosis of paediatric and adult-onset inflammatory bowel disease in Korea: a nationwide population-based study.
     Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17125.
     PubMed     Abstract available
     
     
     
240. BIRON A, Beaugerie L, Chazouilleres O, Kirchgesner J, et al
     Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Jul 4. doi: 10.1111/apt.17123.
     PubMed     Abstract available
     
     
     
241. SAND JR, Troelsen FS, Horvath-Puho E, Henderson VW, et al
     Risk of dementia in patients with inflammatory bowel disease: a Danish population-based study.
     Aliment Pharmacol Ther. 2022 Jul 3. doi: 10.1111/apt.17119.
     PubMed     Abstract available
     
     
     
242. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
     Letter: normalizing the ileoanal pouch-more than a one-step technique. Authors' reply.
     Aliment Pharmacol Ther. 2022;56:176-177.
     PubMed    
     
     
     
243. WEST J, Card TR, Crooks CJ
     Editorial: seeing the light at the end of gastroscope - complications after elective procedures are ready for NICE, bright decision aid tools - authors' reply.
     Aliment Pharmacol Ther. 2022;56:157.
     PubMed    
     
     
     
244. HADI Y, Kochhar GS
     Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic-authors' reply.
     Aliment Pharmacol Ther. 2022;56:178.
     PubMed    
     
     
     
245. LO SW, Garg M, Segal JP
     Letter: normalising the ileoanal pouch-more than a one-step technique.
     Aliment Pharmacol Ther. 2022;56:174-175.
     PubMed    
     
     
     
246. BHURWAL A, Mutneja H, Seril D
     Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain. Authors' reply.
     Aliment Pharmacol Ther. 2022;56:164-165.
     PubMed    
     
     
     
247. BENCHIMOL EI, Kuenzig ME
     Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain.
     Aliment Pharmacol Ther. 2022;56:162-163.
     PubMed    
     
     
     
248. HADI Y, Kochhar GS
     Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2022;56:179.
     PubMed    
     
     
     
249. FEHILY SR, Al-Ani AH, Abdelmalak J, Rentch C, et al
     Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
     Aliment Pharmacol Ther. 2022;56:6-27.
     PubMed     Abstract available
     
     
     
250. VAUGHAN R, Tjandra D, Patwardhan A, Mingos N, et al
     Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease.
     Aliment Pharmacol Ther. 2022;56:84-94.
     PubMed     Abstract available
     
     
     
251. LYONS M, Derikx LAAP, Fulforth J, McCall S, et al
     Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
     Aliment Pharmacol Ther. 2022;56:67-76.
     PubMed     Abstract available
     
     
     
252. ROBLIN X, Veyrard P, Bastide L, Berger AE, et al
     Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
     Aliment Pharmacol Ther. 2022;56:77-83.
     PubMed     Abstract available
     
     
     
253. MASSIRONI S, Vigano C, Danese S
     Letter: pancreatic involvement in inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2022;56:371.
     PubMed    
     
     
     
254. DAI C, Huang YH
     Letter: pancreatic involvement in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;56:370.
     PubMed    
     
     
     
255. SOLITANO V, Armuzzi A
     Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis-a step towards precision medicine?
     Aliment Pharmacol Ther. 2022;56:347-348.
     PubMed    
     
     
     
256. FRIEDMAN S
     Editorial: measuring fertility in men with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;56:345-346.
     PubMed    
     
     
     
257. GILL M, Majumdar A
     Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game.
     Aliment Pharmacol Ther. 2022;56:353-354.
     PubMed    
     
     
     
258. KO KL, Hung IF, Leung WK
     Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game. Authors' reply.
     Aliment Pharmacol Ther. 2022;56:355-356.
     PubMed    
     
     
     
259. MADSEN GR, Wilkens R, Boysen T, Burisch J, et al
     The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases-an international Delphi consensus survey.
     Aliment Pharmacol Ther. 2022;56:263-270.
     PubMed     Abstract available
     
     
     
260. PUGLIESE D, Privitera G, Crispino F, Mezzina N, et al
     Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
     Aliment Pharmacol Ther. 2022;56:95-109.
     PubMed     Abstract available
     
     
     June 2022
261. UMAR N, King D, Chandan JS, Bhala N, et al
     The association between inflammatory bowel disease and mental ill health: A retrospective cohort study using data from UK primary care.
     Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17110.
     PubMed     Abstract available
     
     
     
262. FRIEDMAN S, Garvik OS, Nielsen J, Norgard BM, et al
     Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: A nationwide cohort study.
     Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17113.
     PubMed     Abstract available
     
     
     
263. YUAN WQ, Li F, Yang LC, Yang ZL, et al
     Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic.
     Aliment Pharmacol Ther. 2022;55:1464-1465.
     PubMed    
     
     
     
264. WANG CY, Lai CC
     Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;55:1462-1463.
     PubMed    
     
     
     
265. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
     Defining normal pouch function in patients with ileal pouch-anal anastomosis: a pilot study.
     Aliment Pharmacol Ther. 2022;55:1560-1568.
     PubMed     Abstract available
     
     
     
266. HAWTHORNE AB, Glatter J, Blackwell J, Ainley R, et al
     Inflammatory bowel disease patient-reported quality assessment should drive service improvement: A national survey of UK IBD units and patients.
     Aliment Pharmacol Ther. 2022 Jun 1. doi: 10.1111/apt.17042.
     PubMed     Abstract available
     
     
     May 2022
267. SWAMINATHAN A, Fan D, Borichevsky GM, Mules TC, et al
     The disease severity index for inflammatory bowel disease is associated with psychological symptoms, quality of life and predicts a more complicated disease course.
     Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17058.
     PubMed     Abstract available
     
     
     
268. ROSIOU K, Carbonell J, Dolby V, Monfared N, et al
     Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study.
     Aliment Pharmacol Ther. 2022 May 24. doi: 10.1111/apt.17039.
     PubMed     Abstract available
     
     
     
269. DRUVEFORS E, Andersson RE, Hammar U, Landerholm K, et al
     Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden.
     Aliment Pharmacol Ther. 2022 May 22. doi: 10.1111/apt.16984.
     PubMed     Abstract available
     
     
     
270. KO KL, Lam YF, Cheung KS, Hung IF, et al
     Clinical trial: intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients.
     Aliment Pharmacol Ther. 2022 May 11. doi: 10.1111/apt.16970.
     PubMed     Abstract available
     
     
     
271. TAXONERA C, Fernandez-Acenero MJ, Olivares D, Calvo M, et al
     Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
     Aliment Pharmacol Ther. 2022 May 4. doi: 10.1111/apt.16964.
     PubMed     Abstract available
     
     
     
272. MASSIRONI S, Fanetti I, Vigano C, Pirola L, et al
     Systematic review-Pancreatic involvement in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16949.
     PubMed     Abstract available
     
     
     
273. FALLOON K, Cohen B, Rieder F
     Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2022;55:1208-1209.
     PubMed    
     
     
     
274. HADI Y, Kochhar GS
     Letter: association between COVID-19 and inflammatory bowel disease-Authors' reply.
     Aliment Pharmacol Ther. 2022;55:1228-1229.
     PubMed    
     
     
     
275. KOKKOTIS G, Kitsou K, Bamias G
     Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
     Aliment Pharmacol Ther. 2022;55:1235-1236.
     PubMed    
     
     
     
276. ARDALAN ZS, Friedman AB
     Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment.
     Aliment Pharmacol Ther. 2022;55:1202-1203.
     PubMed    
     
     
     
277. GUILLO L, Peyrin-Biroulet L, Danese S
     Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;55:1206-1207.
     PubMed    
     
     
     
278. BURISCH J, Langholz E, Munkholm P
     Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply.
     Aliment Pharmacol Ther. 2022;55:1239-1240.
     PubMed    
     
     
     
279. CHEN HY, Wang SI, Chang R, Wei JC, et al
     Letter: association between COVID-19 and inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;55:1226-1227.
     PubMed    
     
     
     
280. DEMARZO MG, Viola A, Picci A, Fries W, et al
     Letter: the clinical course of Crohn's disease-the Sicilian experience.
     Aliment Pharmacol Ther. 2022;55:1237-1238.
     PubMed    
     
     
     
281. SAGAMI S, Kobayashi T
     Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment. Authors' reply.
     Aliment Pharmacol Ther. 2022;55:1204-1205.
     PubMed    
     
     
     
282. BACHOUR SP, Shah RS, Lyu R, Rieder F, et al
     Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions.
     Aliment Pharmacol Ther. 2022;55:1139-1150.
     PubMed     Abstract available
     
     
     
283. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
     Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
     Aliment Pharmacol Ther. 2022;55:1151-1159.
     PubMed     Abstract available
     
     
     
284. WANG J, Goren I, Rieder F
     Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply.
     Aliment Pharmacol Ther. 2022;55:1360.
     PubMed    
     
     
     
285. FERNANDES RG, Radford-Smith G
     Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?
     Aliment Pharmacol Ther. 2022;55:1350-1351.
     PubMed    
     
     
     
286. RADEKE HH, Stein J
     Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;55:1359.
     PubMed    
     
     
     
287. OKABAYASHI S, Yamazaki H, Matsuoka K, Yamamoto Y, et al
     Editorial: is older-onset ulcerative colitis more severe or less aggressively managed? Authors' reply.
     Aliment Pharmacol Ther. 2022;55:1352-1353.
     PubMed    
     
     
     
288. KUMAR P, Vuyyuru SK, Kedia S, Ahuja V, et al
     Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF-therapy-authors' reply.
     Aliment Pharmacol Ther. 2022;55:1348-1349.
     PubMed    
     
     
     
289. LOVATT J, Selinger CP
     Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF therapy.
     Aliment Pharmacol Ther. 2022;55:1346-1347.
     PubMed    
     
     
     April 2022
290. VERSTOCKT B, Volk V, Jaeckel C, Alsoud D, et al
     Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
     Aliment Pharmacol Ther. 2022 Apr 28. doi: 10.1111/apt.16955.
     PubMed     Abstract available
     
     
     
291. VANDE CASTEELE N, Sandborn WJ, Feagan BG, Vermeire S, et al
     Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
     Aliment Pharmacol Ther. 2022 Apr 27. doi: 10.1111/apt.16937.
     PubMed     Abstract available
     
     
     
292. BERGQVIST V, Holmgren J, Klintman D, Marsal J, et al
     Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Apr 25. doi: 10.1111/apt.16927.
     PubMed     Abstract available
     
     
     
293. HALFVARSON JF, Ludvigsson JF, Bresso F, Askling J, et al
     Age determines the risk of familial inflammatory bowel disease-A nationwide study.
     Aliment Pharmacol Ther. 2022 Apr 22. doi: 10.1111/apt.16938.
     PubMed     Abstract available
     
     
     
294. MOENS A, Sadat Seyed Tabib N, Ballet V, Sabino J, et al
     Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre.
     Aliment Pharmacol Ther. 2022 Apr 20. doi: 10.1111/apt.16928.
     PubMed     Abstract available
     
     
     
295. KHALILI H, Casey K
     Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
     Aliment Pharmacol Ther. 2022;55:884.
     PubMed    
     
     
     
296. YIN JQ, Wang BQ, Chen ZB, He HD, et al
     Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs.
     Aliment Pharmacol Ther. 2022;55:882-883.
     PubMed    
     
     
     
297. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
     Letter: inflammatory bowel disease services during the Covid-19 pandemic.
     Aliment Pharmacol Ther. 2022;55:1063.
     PubMed    
     
     
     
298. DEPUTY M, Hart A, Faiz O
     Letter: inflammatory bowel disease services during the Covid-19 pandemic - authors' reply.
     Aliment Pharmacol Ther. 2022;55:1064.
     PubMed    
     
     
     
299. SELINGER CP, Lenti MV, De Silvestri A
     Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.
     Aliment Pharmacol Ther. 2022;55:1070-1071.
     PubMed    
     
     
     
300. ADOMI M, Ray A
     Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
     Aliment Pharmacol Ther. 2022;55:1069.
     PubMed    
     
     
     
301. KIM ES, Choi S, Choi SY, Park JH, et al
     NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
     Aliment Pharmacol Ther. 2022;55:1008-1015.
     PubMed     Abstract available
     
     
     
302. ALSOUD D, Verstockt B, Vermeire S
     Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
     Aliment Pharmacol Ther. 2022;55:885-886.
     PubMed    
     
     
     
303. YANG H, Li B, Guo Q, Tang J, et al
     Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
     Aliment Pharmacol Ther. 2022;55:764-777.
     PubMed     Abstract available
     
     
     
304. LENTI MV, Dolby V, Clark T, Hall V, et al
     A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
     Aliment Pharmacol Ther. 2022;55:856-866.
     PubMed     Abstract available
     
     
     March 2022
305. BHURWAL A, Mutneja H, Bansal V, Goel A, et al
     Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression.
     Aliment Pharmacol Ther. 2022 Mar 30. doi: 10.1111/apt.16913.
     PubMed     Abstract available
     
     
     
306. TOWNSEND CM, Lovegrove F, Khanna R, Wilson AS, et al
     Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Mar 21. doi: 10.1111/apt.16883.
     PubMed     Abstract available
     
     
     
307. ZAMANI M, Alizadeh-Tabari S, Singh S, Loomba R, et al
     Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.
     PubMed     Abstract available
     
     
     
308. OKABAYASHI S, Yamazaki H, Tominaga K, Miura M, et al
     Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: A multicentre cohort study.
     Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16865.
     PubMed     Abstract available
     
     
     
309. FALLOON K, Cohen B, Ananthakrishnan AN, Barnes EL, et al
     A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16853.
     PubMed     Abstract available
     
     
     
310. SINGH AK, Jena A, Mahajan G, Mohindra R, et al
     Meta-analysis: Hepatitis B vaccination in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16880.
     PubMed     Abstract available
     
     
     
311. SUNG KY, Zhang B, Wang HE, Bai YM, et al
     Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study.
     Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16856.
     PubMed     Abstract available
     
     
     
312. PANACCIONE R, Abreu MT, Lazariciu I, Mundayat R, et al
     Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open.
     Aliment Pharmacol Ther. 2022 Mar 5. doi: 10.1111/apt.16848.
     PubMed    
     
     
     
313. JAYASOORIYA N, Blackwell J, Saxena S, Bottle A, et al
     Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study.
     Aliment Pharmacol Ther. 2022 Mar 4. doi: 10.1111/apt.16820.
     PubMed     Abstract available
     
     
     
314. SAVELKOUL EHJ, Hoentjen F
     Editorial: anti-TNF combination therapy for inflammatory bowel disease-one size does not fit all.
     Aliment Pharmacol Ther. 2022;55:750-751.
     PubMed    
     
     
     
315. HONAP S, Dart RJ, Samaan MA
     Editorial: protecting hypoxia-inducible factor-1alpha and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis?
     Aliment Pharmacol Ther. 2022;55:733-734.
     PubMed    
     
     
     
316. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
     Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
     Aliment Pharmacol Ther. 2022;55:735-736.
     PubMed    
     
     
     
317. KUMAR P, Vuyyuru SK, Kante B, Sahu P, et al
     Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
     Aliment Pharmacol Ther. 2022 Mar 1. doi: 10.1111/apt.16839.
     PubMed     Abstract available
     
     
     
318. ZHAO M, Sall Jensen M, Knudsen T, Kelsen J, et al
     Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study.
     Aliment Pharmacol Ther. 2022;55:541-557.
     PubMed     Abstract available
     
     
     
319. COLMAN RJ, Xiong Y, Mizuno T, Hyams JS, et al
     Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.
     Aliment Pharmacol Ther. 2022;55:593-603.
     PubMed     Abstract available
     
     
     
320. COHEN NA, Pekow J
     Editorial: time to modify practice and use the modified Rutgeert's score.
     Aliment Pharmacol Ther. 2022;55:754-755.
     PubMed    
     
     
     
321. BANERJEE R, Raghunathan N
     Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease?
     Aliment Pharmacol Ther. 2022;55:740-741.
     PubMed    
     
     
     
322. KIM ES, Kang B
     Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease? Authors' reply.
     Aliment Pharmacol Ther. 2022;55:742-743.
     PubMed    
     
     
     February 2022
323. BALLESTER MP, Mesonero F, Florez-Diez P, Gomez C, et al
     Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study.
     Aliment Pharmacol Ther. 2022 Feb 27. doi: 10.1111/apt.16832.
     PubMed     Abstract available
     
     
     
324. SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
     Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis.
     Aliment Pharmacol Ther. 2022 Feb 25. doi: 10.1111/apt.16817.
     PubMed     Abstract available
     
     
     
325. YE Z, Qian L, Hu W, Miao S, et al
     Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency.
     Aliment Pharmacol Ther. 2022 Feb 20. doi: 10.1111/apt.16837.
     PubMed     Abstract available
     
     
     
326. GROSSBERG LB, Papamichael K, Cheifetz AS
     Review: emerging drug therapies in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16785.
     PubMed     Abstract available
     
     
     
327. WAN J, Wang X, Zhang Y, Chen M, et al
     Systematic review and meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia.
     Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16789.
     PubMed     Abstract available
     
     
     
328. DEPUTY M, Sahnan K, Worley G, Patel K, et al
     The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study.
     Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16800.
     PubMed     Abstract available
     
     
     
329. SCHREIBER S, Irving PM, Sharara AI, Martin-Arranz MD, et al
     Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions.
     Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16781.
     PubMed     Abstract available
     
     
     
330. POLLOK RCG, Jayasooriya N
     Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2022;55:370-371.
     PubMed    
     
     
     
331. TAXONERA C
     Editorial: real-world safety of tofacitinib in ulcerative colitis.
     Aliment Pharmacol Ther. 2022;55:368-369.
     PubMed    
     
     
     
332. MAHMOUD R, Schultheiss JPD, Fidder HH, Oldenburg B, et al
     Letter: loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2022;55:499-500.
     PubMed    
     
     
     
333. BEN-HORIN S, Ungar B
     Letter: loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease depends on treatment duration.
     Aliment Pharmacol Ther. 2022;55:497-498.
     PubMed    
     
     
     
334. GOODSALL TM, Bryant RV
     Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US.
     Aliment Pharmacol Ther. 2022;55:360-361.
     PubMed    
     
     
     
335. ALLOCCA M, Danese S
     Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US. Authors' reply.
     Aliment Pharmacol Ther. 2022;55:362-363.
     PubMed    
     
     
     
336. ALLOCCA M, Craviotto V, Dell'Avalle C, Furfaro F, et al
     Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.
     Aliment Pharmacol Ther. 2022;55:446-454.
     PubMed     Abstract available
     
     
     
337. SKEJO C, Vestergaard T, Julsgaard M
     Editorial: safety of ustekinumab in pregnancy-are we there yet?
     Aliment Pharmacol Ther. 2022;55:495-496.
     PubMed    
     
     
     
338. CARON B, Fumery M, Netter P, Peyrin-Biroulet L, et al
     Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.
     Aliment Pharmacol Ther. 2022;55:508-509.
     PubMed    
     
     
     
339. PARROT L, Dong C, Carbonnel F, Meyer A, et al
     Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
     Aliment Pharmacol Ther. 2022;55:380-388.
     PubMed     Abstract available
     
     
     January 2022
340. THOMSEN SB, Ungaro RC, Allin KH, Elmahdi R, et al
     Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
     Aliment Pharmacol Ther. 2022 Jan 25. doi: 10.1111/apt.16777.
     PubMed     Abstract available
     
     
     
341. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
     Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1alpha stabiliser, for treatment of ulcerative colitis.
     Aliment Pharmacol Ther. 2022 Jan 10. doi: 10.1111/apt.16753.
     PubMed     Abstract available
     
     
     
342. VEISMAN I, Ben-Horin S
     Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients.
     Aliment Pharmacol Ther. 2022;55:131-132.
     PubMed    
     
     
     
343. LAHARIE D, Riviere P
     Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitis.
     Aliment Pharmacol Ther. 2022;55:129-130.
     PubMed    
     
     
     
344. CARBONNEL F, Meyer A
     Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences.
     Aliment Pharmacol Ther. 2022;55:251-252.
     PubMed    
     
     
     
345. GOREN I, Yanai H
     Editorial: risk of loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease-the longer the less?
     Aliment Pharmacol Ther. 2022;55:244-245.
     PubMed    
     
     
     
346. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
     Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences. Authors' reply.
     Aliment Pharmacol Ther. 2022;55:253-254.
     PubMed    
     
     
     
347. VASUDEVAN A, van Langenberg DR
     Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy.
     Aliment Pharmacol Ther. 2022;55:108-109.
     PubMed    
     
     
     
348. BURISCH J, Langholz E, Munkholm P
     Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy-authors' reply.
     Aliment Pharmacol Ther. 2022;55:110-111.
     PubMed    
     
     
     
349. KHAN N, Patel D, Trivedi C, Pernes T, et al
     The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients.
     Aliment Pharmacol Ther. 2022;55:64-72.
     PubMed     Abstract available
     
     
     
350. BURISCH J, Lophaven S, Langholz E, Munkholm P, et al
     The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017.
     Aliment Pharmacol Ther. 2022;55:73-82.
     PubMed     Abstract available
     
     
     
351. REZAZADEH ARDABILI A, Mujagic Z, Jonkers DMAE, Pierik MJ, et al
     Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring.
     Aliment Pharmacol Ther. 2022;55:260-261.
     PubMed    
     
     
     
352. SCHULTHEISS JPD, Mahmoud R, Fidder HH, Oldenburg B, et al
     Editorial: risk of loss of response to anti TNFalpha in patients with inflammatory bowel diseases - the longer the less? Authors' reply.
     Aliment Pharmacol Ther. 2022;55:246.
     PubMed    
     
     
     
353. KHAN N, Yang YX
     Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring. Authors' reply.
     Aliment Pharmacol Ther. 2022;55:262.
     PubMed    
     
     
     
354. MA C, MacDonald JK, Nguyen TM, Chang J, et al
     Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis.
     Aliment Pharmacol Ther. 2022;55:178-190.
     PubMed     Abstract available
     
     
     December 2021
355. WANG J, Goren I, Yang B, Lin S, et al
     The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Dec 21. doi: 10.1111/apt.16741.
     PubMed     Abstract available
     
     
     
356. FLANAGAN E, Prentice R, Wright EK, Gibson PR, et al
     Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.
     Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16739.
     PubMed     Abstract available
     
     
     
357. FORSS A, Clements M, Bergman D, Roelstraete B, et al
     A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014.
     Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16735.
     PubMed     Abstract available
     
     
     
358. HADI Y, Dulai PS, Kupec J, Mohy-Ud-Din N, et al
     Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis.
     Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16730.
     PubMed     Abstract available
     
     
     
359. CASEY K, Lopes EW, Niccum B, Burke K, et al
     Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts.
     Aliment Pharmacol Ther. 2021 Dec 8. doi: 10.1111/apt.16731.
     PubMed     Abstract available
     
     
     
360. MESERVE J, Singh S
     Editorial: risk of pneumonia in IBD-reading between the lines!
     Aliment Pharmacol Ther. 2021;54.
     PubMed    
     
     
     
361. HAMDEH S, Micic D, Hanauer S
     Review article: drug-induced small bowel injury.
     Aliment Pharmacol Ther. 2021;54.
     PubMed     Abstract available
     
     
     
362. SANDBORN WJ, Lawendy N, Danese S, Su C, et al
     Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
     Aliment Pharmacol Ther. 2021 Dec 1. doi: 10.1111/apt.16712.
     PubMed     Abstract available
     
     
     November 2021
363. ZHAO M, Feng R, Ben-Horin S, Zhuang X, et al
     Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations.
     Aliment Pharmacol Ther. 2021 Nov 24. doi: 10.1111/apt.16703.
     PubMed     Abstract available
     
     
     
364. RADHAKRISHNAN ST, Alexander JL, Mullish BH, Gallagher KI, et al
     Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Nov 9. doi: 10.1111/apt.16656.
     PubMed     Abstract available
     
     
     
365. CHAO K, Huang Y, Zhu X, Tang J, et al
     Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.
     Aliment Pharmacol Ther. 2021;54:1124-1133.
     PubMed     Abstract available
     
     
     October 2021
366. BURISCH J, Lophaven S, Munkholm P, Langholz E, et al
     Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort.
     Aliment Pharmacol Ther. 2021 Oct 29. doi: 10.1111/apt.16677.
     PubMed     Abstract available
     
     
     
367. BEZZIO C, Armuzzi A, Furfaro F, Ardizzone S, et al
     Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
     Aliment Pharmacol Ther. 2021 Oct 25. doi: 10.1111/apt.16663.
     PubMed     Abstract available
     
     
     
368. PASVOL TJ, Bloom S, Segal AW, Rait G, et al
     Use of contraceptives and risk of inflammatory bowel disease: A nested case-control study.
     Aliment Pharmacol Ther. 2021 Oct 18. doi: 10.1111/apt.16647.
     PubMed     Abstract available
     
     
     
369. RUBIN DT, Modesto I, Vermeire S, Danese S, et al
     Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
     Aliment Pharmacol Ther. 2021 Oct 9. doi: 10.1111/apt.16619.
     PubMed     Abstract available
     
     
     
370. FEAGAN BG, Khanna R, Sandborn WJ, Vermeire S, et al
     Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
     Aliment Pharmacol Ther. 2021 Oct 6. doi: 10.1111/apt.16626.
     PubMed     Abstract available
     
     
     
371. TAKENAKA K, Kawamoto A, Ohtsuka K
     Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease-authors' reply.
     Aliment Pharmacol Ther. 2021;54:1087.
     PubMed    
     
     
     
372. RAKOWSKY S, Cheifetz AS, Papamichael K
     Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
     Aliment Pharmacol Ther. 2021;54:1085-1086.
     PubMed    
     
     
     
373. JOLVING LR, Anru PL, Nielsen J, Friedman S, et al
     The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines.
     Aliment Pharmacol Ther. 2021;54:1061-1069.
     PubMed     Abstract available
     
     
     
374. SAINZ E, Zabana Y, Miguel I, Fernandez-Clotet A, et al
     Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study).
     Aliment Pharmacol Ther. 2021;54:1041-1051.
     PubMed     Abstract available
     
     
     
375. TAKENAKA K, Kawamoto A, Hibiya S, Suzuki K, et al
     Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
     Aliment Pharmacol Ther. 2021;54:1052-1060.
     PubMed     Abstract available
     
     
     September 2021
376. MULES TC, Swaminathan A, Hirschfeld E, Borichevsky G, et al
     The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease-results from the Stress, Anxiety and Depression with Disease Activity (SADD) Study.
     Aliment Pharmacol Ther. 2021 Sep 29. doi: 10.1111/apt.16616.
     PubMed     Abstract available
     
     
     
377. SCHULTHEISS JPD, Mahmoud R, Louwers JM, van der Kaaij MT, et al
     Loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16605.
     PubMed     Abstract available
     
     
     
378. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
     Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.
     Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16609.
     PubMed     Abstract available
     
     
     
379. DOHERTY J, Fennessy S, Stack R, O' Morain N, et al
     Review Article: Vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
     Aliment Pharmacol Ther. 2021 Sep 2. doi: 10.1111/apt.16590.
     PubMed     Abstract available
     
     
     
380. SAITTA D, Garg M
     Letter: missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease-still significant room for improvement.
     Aliment Pharmacol Ther. 2021;54:734-735.
     PubMed    
     
     
     
381. BLESL A, Hogenauer C, Borenich A, Berghold A, et al
     Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
     Aliment Pharmacol Ther. 2021;54:720-721.
     PubMed    
     
     
     
382. BLESL A, Binder L, Hogenauer C, Wenzl H, et al
     Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
     Aliment Pharmacol Ther. 2021;54:667-677.
     PubMed     Abstract available
     
     
     
383. VISURI I, Eriksson C, Olen O, Cao Y, et al
     Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
     Aliment Pharmacol Ther. 2021;54:848-849.
     PubMed    
     
     
     
384. VEYRARD P, Nancey S, Roblin X
     Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?
     Aliment Pharmacol Ther. 2021;54:843-844.
     PubMed    
     
     
     
385. BERNSTEIN CN, Tennakoon A, Singh H, Targownik L, et al
     Editorial: 5-ASA in IBD patients on biologics-'stop or continue'? Authors' reply.
     Aliment Pharmacol Ther. 2021;54:845.
     PubMed    
     
     
     
386. HAYDEK JP, Scott FI
     Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence.
     Aliment Pharmacol Ther. 2021;54:846-847.
     PubMed    
     
     
     
387. PIERRE N, Salee C, Vieujean S, Bequet E, et al
     Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology.
     Aliment Pharmacol Ther. 2021;54:779-791.
     PubMed     Abstract available
     
     
     
388. BERNSTEIN CN, Tenakoon A, Singh H, Targownik LE, et al
     Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study.
     Aliment Pharmacol Ther. 2021;54:814-832.
     PubMed     Abstract available
     
     
     August 2021
389. SLEUTJES JAM, Roeters van Lennep JE, Boersma E, Menchen LA, et al
     Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.
     Aliment Pharmacol Ther. 2021 Aug 28. doi: 10.1111/apt.16580.
     PubMed     Abstract available
     
     
     
390. HONAP S, Pavlidis P, Irving PM
     Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
     Aliment Pharmacol Ther. 2021;54:341-342.
     PubMed    
     
     
     
391. BIEMANS VBC, Straatmijer T, Hoentjen F, Pierik MJ, et al
     Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
     Aliment Pharmacol Ther. 2021;54:534-535.
     PubMed    
     
     
     
392. LO SW, Connell W, Kamm MA, Lust M, et al
     Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
     Aliment Pharmacol Ther. 2021;54:532-533.
     PubMed    
     
     
     
393. ROBLIN X, Nancey S, Paul S
     Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
     Aliment Pharmacol Ther. 2021;54:538-539.
     PubMed    
     
     
     
394. FRIEDMAN AB, Gibson PR
     Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply.
     Aliment Pharmacol Ther. 2021;54:510.
     PubMed    
     
     
     
395. HORJUS-TALABUR HORJE CS, van Bodegraven AA
     Editorial: assessment of inflammatory bowel disease-a picture is worth a thousand words.
     Aliment Pharmacol Ther. 2021;54:508-509.
     PubMed    
     
     
     
396. TSOI AH, Murugasu A, Garg M
     Letter: assessment of histological disease activity in Crohn's disease clinical trials-a step in the right direction, but further optimisation needed.
     Aliment Pharmacol Ther. 2021;54:541-542.
     PubMed    
     
     
     
397. DEMARZO MG, Bodini G, Giuliana E, Zentilin P, et al
     Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies.
     Aliment Pharmacol Ther. 2021;54:536-537.
     PubMed    
     
     
     
398. MATTOO VY, Basnayake C, Connell WR, Ding N, et al
     Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
     Aliment Pharmacol Ther. 2021;54:249-266.
     PubMed     Abstract available
     
     
     July 2021
399. LAMBERT K, Pappas D, Miglioretto C, Javadpour A, et al
     Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Jul 29. doi: 10.1111/apt.16549.
     PubMed     Abstract available
     
     
     
400. FUMERY M, Filippi J, Abitbol V, Biron A, et al
     Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
     Aliment Pharmacol Ther. 2021 Jul 23. doi: 10.1111/apt.16544.
     PubMed     Abstract available
     
     
     
401. VISURI I, Eriksson C, Olen O, Cao Y, et al
     Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
     Aliment Pharmacol Ther. 2021 Jul 19. doi: 10.1111/apt.16525.
     PubMed     Abstract available
     
     
     
402. MCGING JJ, Radford SJ, Francis ST, Serres S, et al
     Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies.
     Aliment Pharmacol Ther. 2021 Jul 6. doi: 10.1111/apt.16465.
     PubMed     Abstract available
     
     
     
403. LUBER RP, O'Neill R, Singh S, Sharma E, et al
     An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
     Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
     PubMed     Abstract available
     
     
     
404. ROTONDO-TRIVETTE S, Wang B, Gayer C, Parsana R, et al
     Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.
     Aliment Pharmacol Ther. 2021 Jul 4. doi: 10.1111/apt.16496.
     PubMed     Abstract available
     
     
     
405. OSENI E, Sultan K
     Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.
     Aliment Pharmacol Ther. 2021;54:92-93.
     PubMed    
     
     
     
406. JORDI SBU, Misselwitz B, Begre S
     Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2021;54:82-83.
     PubMed    
     
     
     
407. KNOWLES SR, Mikocka-Walus A
     Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021;54:80-81.
     PubMed    
     
     
     
408. FAN D, Gearry RB
     Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
     Aliment Pharmacol Ther. 2021;54:208-209.
     PubMed    
     
     
     
409. TASSONE D, Singh S, Sheng Ding N
     Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
     Aliment Pharmacol Ther. 2021;54:206-207.
     PubMed    
     
     
     
410. MEYER A, Semenzato L, Zureik M, Weill A, et al
     Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
     Aliment Pharmacol Ther. 2021;54:160-166.
     PubMed     Abstract available
     
     
     
411. CASANOVA MJ, Chaparro M, Gisbert JP
     Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
     Aliment Pharmacol Ther. 2021;54:86-87.
     PubMed    
     
     
     
412. PUGLIESE D, Armuzzi A
     Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
     Aliment Pharmacol Ther. 2021;54:84-85.
     PubMed    
     
     
     
413. WEISSHOF R, Chowers Y, Kurnik D
     Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.
     Aliment Pharmacol Ther. 2021;54:88-89.
     PubMed    
     
     
     June 2021
414. FARRAYE FA, Qazi T, Kotze PG, Moore GT, et al
     The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
     Aliment Pharmacol Ther. 2021 Jun 24. doi: 10.1111/apt.16439.
     PubMed     Abstract available
     
     
     
415. MEYER A, Drouin J, Weill A, Carbonnel F, et al
     Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
     Aliment Pharmacol Ther. 2021 Jun 23. doi: 10.1111/apt.16448.
     PubMed     Abstract available
     
     
     
416. FRIEDMAN AB, Asthana A, Knowles SR, Robbins A, et al
     Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16452.
     PubMed     Abstract available
     
     
     
417. BERNSTEIN CN, Nugent Z, Shaffer S, Singh H, et al
     Comorbidity before and after a diagnosis of inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16444.
     PubMed     Abstract available
     
     
     
418. UZZAN M, Bresteau C, Laharie D, Stefanescu C, et al
     Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
     Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16463.
     PubMed     Abstract available
     
     
     
419. KO Y, Paramsothy S, Yau Y, Leong RW, et al
     Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
     Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16436.
     PubMed     Abstract available
     
     
     
420. VAN LINSCHOTEN RCA, Visser E, Niehot CD, van der Woude CJ, et al
     Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
     Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16445.
     PubMed     Abstract available
     
     
     
421. FAIRBRASS KM, Gracie DJ, Ford AC
     Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16454.
     PubMed     Abstract available
     
     
     
422. LAMB CA, Sebastian S, Kent AJ, Segal JP, et al
     Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
     Aliment Pharmacol Ther. 2021;53:1236-1240.
     PubMed    
     
     
     
423. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
     Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.
     Aliment Pharmacol Ther. 2021;53:1234-1235.
     PubMed    
     
     
     
424. VERNON-ROBERTS A, Day AS
     Editorial: trends in paediatric inflammatory bowel disease attributable direct costs.
     Aliment Pharmacol Ther. 2021;53:1232-1233.
     PubMed    
     
     
     
425. TANNOURY J, Amiot A
     Editorial: determining disability in inflammatory bowel disease-"See(k) and you shall find". Authors' reply.
     Aliment Pharmacol Ther. 2021;53:1323.
     PubMed    
     
     
     
426. TURBAYNE AKB, Ward MG
     Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.
     Aliment Pharmacol Ther. 2021;53:1317-1318.
     PubMed    
     
     
     
427. ROBLIN X, Nancey S, Paul S
     Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:1319-1320.
     PubMed    
     
     
     
428. LIMDI JK
     Editorial: determining disability in IBD - 'See(k) and you shall find'.
     Aliment Pharmacol Ther. 2021;53:1321-1322.
     PubMed    
     
     
     
429. MANLAY L, Boschetti G, Pereira B, Flourie B, et al
     Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
     Aliment Pharmacol Ther. 2021;53:1289-1299.
     PubMed     Abstract available
     
     
     May 2021
430. JORDI SBU, Botte F, Lang BM, Greuter T, et al
     Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 May 11. doi: 10.1111/apt.16365.
     PubMed     Abstract available
     
     
     
431. CASANOVA MJ, Chaparro M, Nantes O, Benitez JM, et al
     Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
     Aliment Pharmacol Ther. 2021 May 7. doi: 10.1111/apt.16361.
     PubMed     Abstract available
     
     
     
432. SRINIVASAN A, Haifer C, Thin L
     Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.
     Aliment Pharmacol Ther. 2021;53:1038-1039.
     PubMed    
     
     
     
433. WILSON A, Kim RB
     Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-alpha antagonist immunogenicity - does location matter?
     Aliment Pharmacol Ther. 2021;53:1055-1056.
     PubMed    
     
     
     
434. DEMARZO MG, Bodini G, Vanello M, Martini M, et al
     Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.
     Aliment Pharmacol Ther. 2021;53:1044-1045.
     PubMed    
     
     
     
435. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
     Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:1046-1047.
     PubMed    
     
     
     
436. MESONERO F, Castro-Poceiro J, Benitez JM, Camps B, et al
     Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry.
     Aliment Pharmacol Ther. 2021;53:1021-1029.
     PubMed     Abstract available
     
     
     
437. SEDANO R, Ma C, Jairath V
     Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:1149-1150.
     PubMed    
     
     
     
438. LAUBE R, Selinger CP
     Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction.
     Aliment Pharmacol Ther. 2021;53:1147-1148.
     PubMed    
     
     
     
439. TANNOURY J, Nachury M, Martins C, Serrero M, et al
     Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
     Aliment Pharmacol Ther. 2021;53:1098-1107.
     PubMed     Abstract available
     
     
     
440. TJANDRA D, Garg M, Behrenbruch C, McCormick J, et al
     Review article: investigation and management of internal fistulae in Crohn's disease.
     Aliment Pharmacol Ther. 2021;53:1064-1079.
     PubMed     Abstract available
     
     
     April 2021
441. DHALIWAL J, McKay HE, Deslandres C, Debruyn J, et al
     One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
     Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
     PubMed     Abstract available
     
     
     
442. TOURNIER Q, Paul S, Williet N, Berger AE, et al
     Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Apr 19. doi: 10.1111/apt.16333.
     PubMed     Abstract available
     
     
     
443. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
     Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis.
     Aliment Pharmacol Ther. 2021 Apr 9. doi: 10.1111/apt.16358.
     PubMed     Abstract available
     
     
     
444. VAN DER HAVE M, Maljaars J
     Editorial: opioids in inflammatory bowel disease-primum non nocere.
     Aliment Pharmacol Ther. 2021;53:844-845.
     PubMed    
     
     
     
445. RHUDY C, Perry CL, Barrett TA
     Editorial: opioids in inflammatory bowel disease-primum non nocere. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:846.
     PubMed    
     
     
     
446. JANGI S, Yoon H, Dulai P, Valasek M, et al
     Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply.
     Aliment Pharmacol Ther. 2021;53:957-958.
     PubMed    
     
     
     
447. MAEDA Y, Kudo SE, Takishima K, Misawa M, et al
     Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis.
     Aliment Pharmacol Ther. 2021;53:955-956.
     PubMed    
     
     
     
448. PRENTICE RE, Hollingsworth L, Middleton C, Wilson J, et al
     Letter: colorectal cancer surveillance in inflammatory bowel disease-a call for systematic reform.
     Aliment Pharmacol Ther. 2021;53:953-954.
     PubMed    
     
     
     
449. LUBELL JM
     Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes.
     Aliment Pharmacol Ther. 2021;53:851-852.
     PubMed    
     
     
     
450. BAGER P, Hvas C, Rud C, Dahlerup J, et al
     Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:853-854.
     PubMed    
     
     
     
451. LIM G, Kassam Z, Seow CH
     Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?
     Aliment Pharmacol Ther. 2021;53:855-856.
     PubMed    
     
     
     
452. TURSI A, Mocci G, Picchio M, Elisei W, et al
     Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
     Aliment Pharmacol Ther. 2021;53:859-860.
     PubMed    
     
     
     
453. LAHARIE D, Riviere P
     Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' reply.
     Aliment Pharmacol Ther. 2021;53:857-858.
     PubMed    
     
     
     
454. ALMRADI A, Ma C, D'Haens GR, Sandborn WJ, et al
     An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
     Aliment Pharmacol Ther. 2021;53:784-793.
     PubMed     Abstract available
     
     
     
455. ABUSHAMMA S, Deepak P
     Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials-is it ready for prime time yet?
     Aliment Pharmacol Ther. 2021;53:946-947.
     PubMed    
     
     
     
456. JAIRATH V, Almradi A, Pai RK, Ma C, et al
     Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:952.
     PubMed    
     
     
     
457. TANDON P, Narula N
     Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
     Aliment Pharmacol Ther. 2021;53:950-951.
     PubMed    
     
     
     
458. GOODSALL TM, Jairath V, Bryant RV, Ma C, et al
     Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials - is it ready for prime time yet? Authors' reply.
     Aliment Pharmacol Ther. 2021;53:948-949.
     PubMed    
     
     
     
459. GOODSALL TM, Jairath V, Feagan BG, Parker CE, et al
     Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease.
     Aliment Pharmacol Ther. 2021;53:873-886.
     PubMed     Abstract available
     
     
     March 2021
460. WORLEY G, Faiz O
     Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages? Authors' reply.
     Aliment Pharmacol Ther. 2021;53:661-662.
     PubMed    
     
     
     
461. BODGER K
     Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages?
     Aliment Pharmacol Ther. 2021;53:660.
     PubMed    
     
     
     
462. LAHARIE D
     Editorial: is enteral nutrition back in acute severe ulcerative colitis?
     Aliment Pharmacol Ther. 2021;53:745-746.
     PubMed    
     
     
     
463. AL-ANI AH, Prentice RE, Rentsch C, Christensen B, et al
     Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
     Aliment Pharmacol Ther. 2021;53:766-767.
     PubMed    
     
     
     
464. SAHU P, Kedia S, Kumar Vuyyuru S, Travis S, et al
     Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply.
     Aliment Pharmacol Ther. 2021;53:747-748.
     PubMed    
     
     
     
465. O'MORAIN N, Coe C, Mallon P, Twomey P, et al
     Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?
     Aliment Pharmacol Ther. 2021;53:674-675.
     PubMed    
     
     
     
466. PRIVITERA G, Pugliese D, Scaldaferri F, Armuzzi A, et al
     Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.
     Aliment Pharmacol Ther. 2021;53:764-765.
     PubMed    
     
     
     
467. TRYSTRAM N, Abitbol V, Tannoury J, Lecomte M, et al
     Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
     Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16312.
     PubMed     Abstract available
     
     
     
468. KANESHIRO M, Takenaka K, Suzuki K, Fujii T, et al
     Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
     Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16310.
     PubMed     Abstract available
     
     
     
469. MANTZARIS GJ, Bamias G
     Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials-a missing link.
     Aliment Pharmacol Ther. 2021;53:749-750.
     PubMed    
     
     
     
470. ROBLIN X, Paul S, Nancey S
     Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
     Aliment Pharmacol Ther. 2021;53:640-641.
     PubMed    
     
     
     
471. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
     Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.
     Aliment Pharmacol Ther. 2021;53:642-643.
     PubMed    
     
     
     
472. MCCURDY J, Boet S, Rosenfeld G
     Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn's disease?
     Aliment Pharmacol Ther. 2021;53:667-668.
     PubMed    
     
     
     
473. LAFEUILLE P, Hordonneau C, Vignette J, Blayac L, et al
     Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
     Aliment Pharmacol Ther. 2021;53:577-586.
     PubMed     Abstract available
     
     
     
474. LANSDORP CA, Gecse KB, Buskens CJ, Lowenberg M, et al
     Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
     Aliment Pharmacol Ther. 2021;53:587-597.
     PubMed     Abstract available
     
     
     February 2021
475. FLANAGAN E, Wright EK, Hardikar W, Sparrow MP, et al
     Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates.
     Aliment Pharmacol Ther. 2021 Feb 19. doi: 10.1111/apt.16294.
     PubMed     Abstract available
     
     
     
476. JAHRAUS CD
     Editorial: "Please Sir, I want some more" data to guide delivery of abdominopelvic radiotherapy in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021;53:454-455.
     PubMed    
     
     
     
477. AXELRAD JE
     Editorial: immune-mediated diseases-are we closer to disease-defining molecular signatures?
     Aliment Pharmacol Ther. 2021;53:563-564.
     PubMed    
     
     
     
478. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
     Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.
     Aliment Pharmacol Ther. 2021;53:445-446.
     PubMed    
     
     
     
479. WILS P, Pariente B
     Editorial: keep calm and carry on-managing non-TNF antagonist biologics in pregnancy-authors' reply.
     Aliment Pharmacol Ther. 2021;53:452-453.
     PubMed    
     
     
     
480. SEOW CH, Ma C
     Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy.
     Aliment Pharmacol Ther. 2021;53:450-451.
     PubMed    
     
     
     
481. TOWNSEND T, Subramanian S
     Editorial: vedolizumab in inflammatory bowel diseases-less is more?
     Aliment Pharmacol Ther. 2021;53:443-444.
     PubMed    
     
     
     
482. MESERVE J, Facciorusso A, Holmer AK, Annese V, et al
     Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
     Aliment Pharmacol Ther. 2021;53:374-382.
     PubMed     Abstract available
     
     
     January 2021
483. RHUDY C, Perry CL, Singleton M, Talbert J, et al
     Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2021 Jan 26. doi: 10.1111/apt.16269.
     PubMed     Abstract available
     
     
     
484. SAHU P, Kedia S, Vuyyuru SK, Bajaj A, et al
     Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis.
     Aliment Pharmacol Ther. 2021 Jan 13. doi: 10.1111/apt.16249.
     PubMed     Abstract available
     
     
     
485. CHEE D, Kennedy NA, Goodhand JR, Ahmad T, et al
     Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:337-338.
     PubMed    
     
     
     
486. MAHMOUD R, Itzkowitz SH
     Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root.
     Aliment Pharmacol Ther. 2021;53:335-336.
     PubMed    
     
     
     
487. LORD A, Radford-Smith G
     Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis.
     Aliment Pharmacol Ther. 2021;53:368-369.
     PubMed    
     
     
     
488. RIMOLA J, Panes J, Ordas I
     Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease-authors' reply.
     Aliment Pharmacol Ther. 2021;53:207-208.
     PubMed    
     
     
     
489. DEBNATH P, Rathi P
     Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease.
     Aliment Pharmacol Ther. 2021;53:205-206.
     PubMed    
     
     
     
490. MURRAY CD
     Editorial: fatigue-difficult to assess and difficult to treat.
     Aliment Pharmacol Ther. 2021;53:339.
     PubMed    
     
     
     
491. LEBLANC JF, Hart AL
     Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD.
     Aliment Pharmacol Ther. 2021;53:342-343.
     PubMed    
     
     
     
492. TOWNSEND T, Subramanian S
     Letter: propensity score-handle with care. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:362-363.
     PubMed    
     
     
     
493. MACALUSO FS, Orlando A
     Letter: propensity score-handle with care.
     Aliment Pharmacol Ther. 2021;53:360-361.
     PubMed    
     
     
     
494. CARBERY I, Selinger CP
     Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?
     Aliment Pharmacol Ther. 2021;53:346-347.
     PubMed    
     
     
     
495. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
     Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:344-345.
     PubMed    
     
     
     
496. SCHREINER P, von Kanel R, Misselwitz B
     Editorial: fatigue-difficult to assess and difficult to treat. Authors' reply.
     Aliment Pharmacol Ther. 2021;53:340-341.
     PubMed    
     
     
     
497. BERTANI L, Pugliese D, Trico D, Costa F, et al
     Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply.
     Aliment Pharmacol Ther. 2021;53:348-349.
     PubMed    
     
     
     
498. NICE R, Chanchlani N, Green H, Bewshea C, et al
     Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
     Aliment Pharmacol Ther. 2021;53:128-137.
     PubMed     Abstract available
     
     
     
499. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
     Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
     Aliment Pharmacol Ther. 2021;53:265-272.
     PubMed     Abstract available
     
     
     
500. BERTANI L, Trico D, Pugliese D, Privitera G, et al
     Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
     Aliment Pharmacol Ther. 2021;53:273-280.
     PubMed     Abstract available
     
     
     
501. FRAZZONI L, La Marca M, Radaelli F, Spada C, et al
     Systematic review with meta-analysis: the appropriateness of colonoscopy increases the probability of relevant findings and cancer while reducing unnecessary exams.
     Aliment Pharmacol Ther. 2021;53:22-32.
     PubMed     Abstract available
     
     
     
502. PAI RK, Pai RK, Brown I, Choi WT, et al
     The significance of histological activity measurements in immune checkpoint inhibitor colitis.
     Aliment Pharmacol Ther. 2021;53:150-159.
     PubMed     Abstract available
     
     
     
503. UNGARO RC, Hu L, Ji J, Nayar S, et al
     Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease.
     Aliment Pharmacol Ther. 2021;53:281-290.
     PubMed     Abstract available
     
     
     
504. KING D, Coupland B, Dosanjh A, Cole A, et al
     The risk of later surgery at the anastomotic site following right hemicolectomy for Crohn's disease in a national cohort of 12 230 patients.
     Aliment Pharmacol Ther. 2021;53:114-127.
     PubMed     Abstract available
     
     
     December 2020
505. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
     Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
     Aliment Pharmacol Ther. 2020 Dec 19. doi: 10.1111/apt.16193.
     PubMed     Abstract available
     
     
     
506. YE L, Chapman TP, Wen Z, Lin L, et al
     Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
     Aliment Pharmacol Ther. 2020 Dec 12. doi: 10.1111/apt.16130.
     PubMed     Abstract available
     
     
     
507. PIOVANI D, Pansieri C, Peyrin-Biroulet L, Danese S, et al
     Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.
     Aliment Pharmacol Ther. 2020 Dec 9. doi: 10.1111/apt.16222.
     PubMed     Abstract available
     
     
     
508. WILS P, Seksik P, Stefanescu C, Nancey S, et al
     Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
     Aliment Pharmacol Ther. 2020 Dec 7. doi: 10.1111/apt.16192.
     PubMed     Abstract available
     
     
     
509. LO CH, Khalili H, Lochhead P, Song M, et al
     Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.
     Aliment Pharmacol Ther. 2020 Dec 5. doi: 10.1111/apt.16210.
     PubMed     Abstract available
     
     
     
510. WORLEY G, Almoudaris A, Bassett P, Segal J, et al
     Colectomy rates for ulcerative colitis in England 2003-2016.
     Aliment Pharmacol Ther. 2020 Dec 2. doi: 10.1111/apt.16202.
     PubMed     Abstract available
     
     
     
511. REUKEN PA, Wust M, Loffler B, Bauer M, et al
     Letter: SARS-CoV-2-induced gastrointestinal inflammation.
     Aliment Pharmacol Ther. 2020;52.
     PubMed    
     
     
     November 2020
512. DOHOS D, Hanak L, Szakacs Z, Kiss S, et al
     Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2020 Nov 28. doi: 10.1111/apt.16182.
     PubMed     Abstract available
     
     
     
513. BROUSSARD D, Riviere P, Bonnet J, Fotsing G, et al
     Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
     Aliment Pharmacol Ther. 2020 Nov 26. doi: 10.1111/apt.16176.
     PubMed     Abstract available
     
     
     
514. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
     Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.
     Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16166.
     PubMed     Abstract available
     
     
     
515. HIBIYA S, Matsuyama Y, Fujii T, Maeyashiki C, et al
     5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis.
     Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16120.
     PubMed     Abstract available
     
     
     
516. SCHREINER P, Rossel JB, Biedermann L, Valko PO, et al
     Fatigue in inflammatory bowel disease and its impact on daily activities.
     Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16145.
     PubMed     Abstract available
     
     
     
517. GORDON C, Chee D, Hamilton B, Heerasing NM, et al
     Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16155.
     PubMed     Abstract available
     
     
     
518. MEYER A, Drouin J, Weill A, Carbonnel F, et al
     Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018.
     Aliment Pharmacol Ther. 2020;52:1480-1490.
     PubMed     Abstract available
     
     
     
519. NICOLAIDES S, Vasudevan A, van Langenberg D
     Letter: rationalising aminosalicylates in inflammatory bowel disease.
     Aliment Pharmacol Ther. 2020;52:1619-1620.
     PubMed    
     
     
     
520. MA C, Singh S, Heatherington J, Panaccione R, et al
     Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?
     Aliment Pharmacol Ther. 2020;52:1615-1616.
     PubMed    
     
     
     
521. ASSCHER VER, Biemans VBC, Hoentjen F, Maljaars PWJ, et al
     Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.
     Aliment Pharmacol Ther. 2020;52:1617-1618.
     PubMed    
     
     
     
522. CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
     Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
     Aliment Pharmacol Ther. 2020;52:1621.
     PubMed    
     
     
     
523. NARULA N, Aruljothy A, Alshahrani AA, Fadida M, et al
     Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
     Aliment Pharmacol Ther. 2020 Nov 1. doi: 10.1111/apt.16147.
     PubMed     Abstract available
     
     
     
524. VASUDEVAN A, Con D, Nicolaides S, van Langenberg DR, et al
     Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
     Aliment Pharmacol Ther. 2020;52:1529-1530.
     PubMed    
     
     
     
525. ZULFIQAR M, Deepak P
     Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNF-alpha inhibitors in Crohn's disease.
     Aliment Pharmacol Ther. 2020;52:1531-1532.
     PubMed    
     
     
     
526. FRASER AG
     Methotrexate or azathioprine-do differing rates of discontinuation settle the debate?
     Aliment Pharmacol Ther. 2020;52:1527-1528.
     PubMed    
     
     
     
527. FLANAGAN E, Gibson PR, Wright EK, Moore GT, et al
     Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
     Aliment Pharmacol Ther. 2020;52:1551-1562.
     PubMed     Abstract available
     
     
     
528. TAYLOR H, Serrano-Contreras JI, McDonald JAK, Epstein J, et al
     Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
     Aliment Pharmacol Ther. 2020;52:1491-1502.
     PubMed     Abstract available
     
     
     
529. RIMOLA J, Fernandez-Clotet A, Capozzi N, Rojas-Farreras S, et al
     Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
     Aliment Pharmacol Ther. 2020;52:1563-1573.
     PubMed     Abstract available
     
     
     October 2020
530. BANERJEE R, Ravikanth VV, Pal P, Bale G, et al
     NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
     Aliment Pharmacol Ther. 2020 Oct 27. doi: 10.1111/apt.16137.
     PubMed     Abstract available
     
     
     
531. PANACCIONE R, Danese S, Sandborn WJ, O'Brien CD, et al
     Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
     Aliment Pharmacol Ther. 2020 Oct 21. doi: 10.1111/apt.16119.
     PubMed     Abstract available
     
     
     
532. AMIOT A, Salameh R
     Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy-authors' reply.
     Aliment Pharmacol Ther. 2020;52:1252.
     PubMed    
     
     
     
533. FABIAN A, Bor R, Farkas K, Szepes Z, et al
     Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy.
     Aliment Pharmacol Ther. 2020;52:1251.
     PubMed    
     
     
     
534. PRENTICE RE, Tjandra D, Garg M, Lubel JS, et al
     Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
     Aliment Pharmacol Ther. 2020;52:1422-1423.
     PubMed    
     
     
     
535. BRITTON E, Richardson P, Mian I, Conley T, et al
     Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when?
     Aliment Pharmacol Ther. 2020;52:1414-1415.
     PubMed    
     
     
     
536. BIEMANS VBC, Hoentjen F, Pierik MJ
     Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
     Aliment Pharmacol Ther. 2020;52:1255-1256.
     PubMed    
     
     
     
537. LIU K, Cai F, Huang J
     Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
     Aliment Pharmacol Ther. 2020;52:1253-1254.
     PubMed    
     
     
     
538. LAHARIE D, Riviere P
     Editorial: biologics in the therapy of Crohn's disease-the fog clears.
     Aliment Pharmacol Ther. 2020;52:1214-1215.
     PubMed    
     
     
     
539. MERTZ NORGARD B, Friedman S
     Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data. Authors' reply.
     Aliment Pharmacol Ther. 2020;52:1411.
     PubMed    
     
     
     
540. BETTENWORTH D, Bokemeyer A, Kou L, Lopez R, et al
     Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.
     Aliment Pharmacol Ther. 2020;52:1104-1116.
     PubMed     Abstract available
     
     
     
541. TOWNSEND T, Razanskaite V, Dodd S, Storey D, et al
     Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
     Aliment Pharmacol Ther. 2020;52:1341-1352.
     PubMed     Abstract available
     
     
     September 2020
542. BATTAT R, Vande Casteele N, Pai RK, Wang Z, et al
     Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
     Aliment Pharmacol Ther. 2020 Sep 27. doi: 10.1111/apt.16083.
     PubMed     Abstract available
     
     
     
543. JANGI S, Yoon H, Dulai PS, Valasek M, et al
     Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
     Aliment Pharmacol Ther. 2020;52:1008-1016.
     PubMed     Abstract available
     
     
     
544. CHEE D, Goodhand JR, Ahmad T
     Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?
     Aliment Pharmacol Ther. 2020;52:1076-1077.
     PubMed    
     
     
     
545. APPLETON L, Day AS
     Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
     Aliment Pharmacol Ther. 2020;52:1080-1081.
     PubMed    
     
     
     
546. ROBLIN X, Le Roy B, Paul S
     Editorial: therapeutic drug monitoring for golimumab - ready for prime time?
     Aliment Pharmacol Ther. 2020;52:1078-1079.
     PubMed    
     
     
     
547. BERTANI L, Fornai M, Antonioli L, Blandizzi C, et al
     Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply.
     Aliment Pharmacol Ther. 2020;52:1082.
     PubMed    
     
     
     
548. KOPYLOV U
     Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
     Aliment Pharmacol Ther. 2020;52:907.
     PubMed    
     
     
     
549. DESAI D, Abraham P
     Letter: monitoring interval for thiopurine therapy - a comment.
     Aliment Pharmacol Ther. 2020;52:910.
     PubMed    
     
     
     
550. HUDSON J, Herfarth HH, Barnes EL
     Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
     Aliment Pharmacol Ther. 2020;52:906.
     PubMed    
     
     
     
551. JONES K, Baker K, Speight RA, Thompson NP, et al
     Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease.
     Aliment Pharmacol Ther. 2020;52:964-975.
     PubMed     Abstract available
     
     
     
552. BROMS G, Kieler H, Ekbom A, Gissler M, et al
     Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
     Aliment Pharmacol Ther. 2020;52:843-854.
     PubMed     Abstract available
     
     
     
553. IBORRA M, Beltran B, Fernandez-Clotet A, Iglesias-Flores E, et al
     Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
     Aliment Pharmacol Ther. 2020;52:1017-1030.
     PubMed     Abstract available
     
     
     August 2020
554. KHAN MU, Mushtaq K, Al-Ejji KMAA, Yakoob RA, et al
     Letter: IBD nurse-a pivotal role in the time of the pandemic.
     Aliment Pharmacol Ther. 2020;52:745.
     PubMed    
     
     
     
555. BERTANI L, Antonioli L, Blandizzi C
     Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
     Aliment Pharmacol Ther. 2020;52:751-752.
     PubMed    
     
     
     
556. AL-ANI AH, Rentsch CA, Azim S, Bidgood E, et al
     Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.
     Aliment Pharmacol Ther. 2020;52:746-747.
     PubMed    
     
     
     
557. BIEMANS VBC, Hoentjen F, Pierik MJ
     Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
     Aliment Pharmacol Ther. 2020;52:753-754.
     PubMed    
     
     
     
558. MARSH A, Radford-Smith G
     Editorial: obesity management and IBD-weight loss reduces IBD risk.
     Aliment Pharmacol Ther. 2020;52:731-732.
     PubMed    
     
     
     
559. KANG B, Kim TJ, Choi J, Baek SY, et al
     Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
     Aliment Pharmacol Ther. 2020;52:459-470.
     PubMed     Abstract available
     
     
     
560. WALKER GJ, Lin S, Chanchlani N, Thomas A, et al
     Quality improvement project identifies factors associated with delay in IBD diagnosis.
     Aliment Pharmacol Ther. 2020;52:471-480.
     PubMed     Abstract available
     
     
     
561. BOHM M, Xu R, Zhang Y, Varma S, et al
     Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
     Aliment Pharmacol Ther. 2020;52:669-681.
     PubMed     Abstract available
     
     
     
562. SEGAL JP, Smith PJ
     Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis.
     Aliment Pharmacol Ther. 2020;52:733-734.
     PubMed    
     
     
     July 2020
563. BIEMANS VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, et al
     Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
     Aliment Pharmacol Ther. 2020;52:123-134.
     PubMed     Abstract available
     
     
     
564. KABIR M, Fofaria R, Arebi N, Bassett P, et al
     Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present).
     Aliment Pharmacol Ther. 2020;52:5-19.
     PubMed     Abstract available
     
     
     
565. KOPYLOV U, Hanzel J, Liefferinckx C, De Marco D, et al
     Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
     Aliment Pharmacol Ther. 2020;52:135-142.
     PubMed     Abstract available
     
     
     
566. KOCHAR B, Cai W, Cagan A, Ananthakrishnan AN, et al
     Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases.
     Aliment Pharmacol Ther. 2020;52:311-318.
     PubMed     Abstract available
     
     
     
567. THOMANN AK, Mak JWY, Zhang JW, Wuestenberg T, et al
     Review article: bugs, inflammation and mood-a microbiota-based approach to psychiatric symptoms in inflammatory bowel diseases.
     Aliment Pharmacol Ther. 2020;52:247-266.
     PubMed     Abstract available
     
     
     
568. DUMONT LM, Landman C, Sokol H, Beaugerie L, et al
     Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
     Aliment Pharmacol Ther. 2020;52:303-310.
     PubMed     Abstract available
     
     
     
569. BERTANI L, Fornai M, Fornili M, Antonioli L, et al
     Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
     Aliment Pharmacol Ther. 2020;52:284-291.
     PubMed     Abstract available
     
     
     June 2020
570. YANG E, Panaccione N, Whitmire N, Dulai PS, et al
     Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
     Aliment Pharmacol Ther. 2020;51:1031-1038.
     PubMed     Abstract available
     
     
     
571. LU C, Baraty B, Lee Robertson H, Filyk A, et al
     Systematic review: medical therapy for fibrostenosing Crohn's disease.
     Aliment Pharmacol Ther. 2020;51:1233-1246.
     PubMed     Abstract available
     
     
     
572. SRINIVASAN A, van Langenberg DR, Little RD, Sparrow MP, et al
     A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
     Aliment Pharmacol Ther. 2020;51:1342-1352.
     PubMed     Abstract available
     
     
     
573. PAPOUTSOPOULOU S, Satsangi J, Campbell BJ, Probert CS, et al
     Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms.
     Aliment Pharmacol Ther. 2020;51:1268-1285.
     PubMed     Abstract available
     
     
     
574. CZAJA AJ
     Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
     Aliment Pharmacol Ther. 2020;51:1286-1304.
     PubMed     Abstract available
     
     
     May 2020
575. UNGARO RC, Aggarwal S, Topaloglu O, Lee WJ, et al
     Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.
     Aliment Pharmacol Ther. 2020;51:831-842.
     PubMed     Abstract available
     
     
     
576. CHEUNG KS, Chen L, Chan EW, Seto WK, et al
     Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer.
     Aliment Pharmacol Ther. 2020;51:899-908.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.